Roche

YTD September 2015 sales

Basel, 22 October 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer

4 Q3 2015: Guidance upgraded to mid-single digit sales growth1, Core EPS ahead of sales growth2

Growth YTD Sept

Sales • Group sales +6%1 driven by HER2 franchise (+19%), Avastin (+9%), Actemra (+22%) and Professional Diagnostics (+7%) • Outperformance in all major regions: US (+6%1), Europe (+3%1), Japan (+6%1) and International (+8%1)

Innovation

Oncology • Atezolizumab: Phase II lung (POPLAR, BIRCH); Phase II bladder (IMvigor 210) • Alectinib: Phase II in 2L ALK+ NSCLC (update) • Cotellic + Zelboraf: Phase III 1L melanoma (coBRIM), overall survival

Neuroscience • Ocrelizumab: – Phase III RMS (OPERA I/II) met primary and key secondary endpoints – Phase III PPMS (ORATORIO) met primary and key secondary endpoints

Diagnostics • Launch of cobas EGFR Mutation Test v2 - first Roche liquid biopsy PCR test

1 At constant exchange rates (CER) 5 2 Excluding sale of filgrastim rights in 2014 YTD Sept 2015: Strong sales growth continues

2015 2014 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 27.7 27.0 3 6

Diagnostics Division 7.8 7.8 1 6

Roche Group 35.5 34.8 2 6

CER=constant exchange rates 6 Q3 2015: Sales growth for fifth consecutive year

10%

8% 8% 7% 7% 6% 6% 6% 6% 6% 6% 5% 5% 4% 5% 4% 4% 4% 4%

2% 2% 0% 0% 1% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15

All growth rates at constant exchange rates (CER) 7 YTD Sept 2015: Strong sales growth in all regions

CHFbn 18 +6% 15 +1% 12 +3% +8% 9 Diagnostics +2% +14% +7% Pharma 6 +6% -5% +3% 3 +6% +8% 0 Japan International Europe US

All growth rates at constant exchange rates (CER) 8 Roche: Significantly advancing patient care Recognising innovation 2013-15

Breakthrough Therapy 9 Designations Actemra (Systemic sclerosis) Venetoclax (R/R CLL 17p) YTD 2015 Rank Company # Atezolizumab (NSCLC) 1 Roche 9 ACE 910 (Hemophilia) 2 BMS 8 Esbriet (IPF) 3 Novartis 6 2014 Lucentis (DR) 4 GSK 5 Atezolizumab (Bladder) 4 Merck 5 Alectinib (2L ALK+ NSCLC) 2013 5 JNJ 4 Gazyva (1L CLL)

Source: http://www.focr.org/breakthrough-therapies as at 9 September 2015; CLL=Chronic Lymphocytic Leukemia; NSCLC=Non- 9 Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Hypertension; DR=Diabetic Retinopathy Pharma: Making a difference for patients Significant opportunities ahead

Year Molecule Indication Trial name Event Alectinib ALK+ NSCLC AF-002JG, ACCALIA NME filed 2015 Cotellic+Zelboraf BRAFV600 melanoma coBRIM NME filed Venetoclax 17p del R/R CLL NME filing Atezolizumab 2/3L NSCLC, bladder BIRCH, POPLAR, Imvigor 210 NME filing Ocrelizumab RMS, PPMS OPERA I/II, ORATORIO NME filing 2016 Lebrikizumab Asthma LAVOLTA I/II, ACOUSTICS Pivotal data Perjeta+Herceptin Adjuvant HER2+ breast APHINITY Pivotal data Gazyva Front-line aNHL GOYA Pivotal data ACE 910 Hemophila A Pivotal data Lampalizumab Geographic atrophy CHROMA, SPECTRI Pivotal data 2017 Gazyva 1L iNHL GALLIUM Pivotal data Atezolizumab+chemo 1L NSCLC IMpower 110/150/130/111/131 Pivotal data

Oncology Neuroscience Ophthalmology Immunology

Timelines may change as trials can be event-driven NME=new molecular entity; NSCLC=non-small cell lung cancer; CLL=chronic lymphoid leukemia; RMS=relapsing multiple sclerosis 10 (MS); PPMS=primary progressive MS; aNHL=aggressive non-hodgkin`s lymphoma; iNHL=indolent non-hodgkin`s lymphoma 2015 outlook: Guidance upgraded

Group sales growth1 Mid-single digit

Core EPS growth1 Ahead of sales growth2

Dividend outlook Further increase dividend in Swiss francs

1 At constant exchange rates (CER) 11 2 Excluding sale of filgrastim rights in 2014 Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals

12 YTD Sept 2015 sales

Innovation

Outlook

13 YTD Sept 2015: Pharma sales Strong growth driven by all regions

2015 2014 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 27,690 26,965 3 6 United States 13,047 11,528 13 7 Europe 6,476 7,070 -8 3 Japan 2,341 2,406 -3 8 International 5,826 5,961 -2 6

CER=constant exchange rates 14 YTD Sept 2015: Strong performance from oncology and immunology franchises

Herceptin +10%

Avastin +9%

Perjeta +66%

Esbriet n.a.

MabThera/Rituxan +5%

Kadcyla +57%

Actemra/RoActemra +22%

Xolair +25%

Lucentis -15% US Xeloda -36% Europe Valcyte/Cymevene -47% Japan International Pegasys -48%

-500 -250 0 250 500 CHFm

Absolute amounts and growth rates at constant exchange rates (CER) 15 YTD Sept 2015: Oncology with +8% growth

YoY CER growth Perjeta

HER2 Herceptin +19% • Strong uptake of Perjeta and Kadcyla • Growth of Herceptin due to longer treatment Kadcyla • Growth driven by ovarian and cervical Avastin +9% • International: Growth in all regions

MabThera/ Rituxan +4% • US: Growth in iNHL maintenance (Oncology)

Tarceva -7% • In-class competition

Xeloda -36% • Loss of exclusivity

• Competitive pressure in US and EU Zelboraf -25% • Cotellic + Zelboraf approval expected in 2015

CHFbn 0 1 2 3 4 5 6 7

CER=constant exchange rates 16 YTD September 2015 Oncology sales: CHF 17.6bn; CER growth +8%

HER2 franchise: Growth driven by Herceptin, Perjeta and Kadcyla

CHFm YoY CER growth 2,500 HER2 franchise Q3 2015 +16% • Herceptin (+7%): Longer treatment +23% 2,000 duration in combination with Perjeta +15% • Perjeta (+57%): Strong demand in 1L +16% mBC (US & EU) and neoadjuvant (US) 1,500 • Kadcyla (+44%): Growth driven by EU

1,000 Outlook • Perjeta: Neoadjuvant approval in the EU 500 achieved in Q3 ’15 • Kadcyla: Continued growth to be driven 0 by EU and International Q3 12 Q3 13 Q3 14 Q3 15 Herceptin Perjeta Kadcyla

CER=constant exchange rates 17 Avastin: Growth in various indications and across all regions

CHFm YoY CER growth Avastin Q3 2015 +6% +8% +14% • US (+6%): Continued uptake in lung, 1,600 +11% ovarian and cervical cancer • EU (+5%): Growth in ovarian and cervical 1,200 • International (+16%): Driven by LATAM and China 800 Outlook

400 • Potential filing in mesothelioma • China: Lung cancer indication launched

0 • EU: Avastin + Tarceva filed in lung cancer Q3 12 Q3 13 Q3 14 Q3 15 US Europe International Japan

CER=constant exchange rates 18 Immunology: Strong performance by Xolair, Actemra and MabThera/Rituxan

CHFm YoY CER growth +23% Xolair (+21%) 1,600 • Allergic asthma and strong growth in +15% +15% chronic idiopathic urticaria due to 1,200 +6% longer treatment duration Actemra (+18%) 800 • SC formulation driving growth • Increasing 1L monotherapy leadership 400 focusing on MTX intolerant patients MabThera/Rituxan (+10%) 0 • Continues to grow in rheumatoid Q3 12 Q3 13 Q3 14 Q3 15 arthritis and vasculitis (GPA and MPA) MabThera/Rituxan (RA) Actemra IV Actemra SC Xolair CellCept Pulmozyme Esbriet Other

CER=constant exchange rates; MTX=methotrexate; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis 19

Actemra: Continued uptake in 1L monotherapy SC formulation driving growth in the EU and US

CHFm YoY CER growth

400 +18% 350 +28% +20% +27% +23% +21% 32% 300 +33% +23% +23% +33% 250 +30% +32% +27% +32% 200 +46%

150 68% 100

50

0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15 IV SC

CER=constant exchange rates; IV=intravenous formulation; SC=subcutaneous formulation 20 Lucentis: Competitive pressure continues; ophthalmology pipeline progresses

Lucentis Q3 2015 Lucentis sales (USDm) • Competitive pressure 500 Outlook • Ongoing competition in AMD & DME

400 • Launch in DR ongoing after first-in- class FDA approval in Q1 2015

Pipeline update ophthalmology 300 • Phase II Port Delivery System study for Lucentis started (expect data 2017) • Anti-VEGF/Ang2 biMab moved into

200 phase II in wAMD Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 • Lampalizumab phase III studies in GA 12 12 13 13 13 13 14 14 14 14 15 15 15 well on track (expect data 2017)

wAMD=wet age-related macular degeneration; DME=diabetic macular edema; DR=diabetic retinopathy; GA=geographic atrophy 21 Esbriet: Market leadership in IPF established

Esbriet sales (CHFm) US 157 • New patient numbers on track with 141 shift to office based pulmonologists

EU • Increasing differentiation due to 88 strengthened label including the pooled 1 yr mortality data

Newsflow / Pipeline update 44 36 32 • ERS: Pooled data analysis presented 27 showing a strong trend towards 2 yr mortality benefit • Start of enrolment in IPF (phase II in combination with lebrikizumab) Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15

IPF=idiopathic pulmonary fibrosis 22 YTD Sept 2015 sales

Innovation

Outlook

23 2015 Roche cancer immunotherapy:

Eight NMEs in the clinic T cell Trafficking

Priming & activation

anti-CEA-IL2v FP anti-OX40 anti-CTLA4 anti-CD27* (Celldex) T cell infiltration   entinostat* (Syndax) anti-VEGF (Avastin)  anti-FAP-IL2v FP anti-Ang2/VEGF (vanucizumab) NME (anti-ctyokine)

Antigen presentation

anti-CD40 Cancer T cell recognition CMB305 vaccine* (Immune Design)   T-Vec oncolytic viruses* (Amgen) anti-CEA/CD3 TCB neo-epitope vaccine  anti-CD20/CD3 biMAb anti-HER2/CD3 biMAb ImmTAC* (Immunocore) T cell killing

Clinical development Antigen release anti-PDL1 (atezolizumab) anti-CSF-1R Preclinical development EGFRi (Tarceva) anti-CEA-IL2v FP Established therapies  ALKi (Alectinib) BRAFi (Zelboraf) anti-OX40 * Partnered projects (external) MEKi (Cotellic) IDOi IDOi* (Incyte)  New in 2015 anti-CD20 (Gazyva)   various chemotherapies  anti-FAP-IL2v FP  lenalidomide  anti-TIGIT rociletinib* (Clovis)  IDO1/TDOi* (Curadev) Chen and Mellman. Immunity 2013  24 Roche cancer immunotherapy beginning 2015 Phase I Phase II Phase III aPDL1 aPDL1+IFN-alfa aPDL1 aPDL1 Solid tumors Solid tumors NSCLC (Dx+) 2/3L NSCLC aPDL1+chemo aPDL1+aCD40 aPDL1 Solid tumors Solid tumors 2/3L NSCLC aPDL1+Tarceva aPDL1+Avastin NSCLC 1L Renal aPDL1+Zelboraf aPDL1 Melanoma 1/2L Bladder aPDL1+Cotellic Solid tumors aPDL1+Avastin Solid tumors aPDL1+Gazyva R/R FL / aNHL aPDL1+Avastin+chemo Solid tumors aCSF-1R Solid tumors aCEA-IL2v FP Solid tumors aOX40 Solid tumors aCEA/CD3 TCB aPDL1 trials Solid tumors NMEs monotherapy IDO Solid tumors Immune doublets aPDL1+ipilimumab Solid tumors Status as at December 31, 2014 25 Roche cancer immunotherapy at Q3 2015 Phase I Phase II Phase III aPDL1 IDO aPDL1 aPDL1 Solid tumors Solid tumors  NSCLC (Dx+)  2/3L NSCLC aPDL1+chemo aCSF-1R aPDL1 aPDL1 Solid tumors Solid tumors 2/3L NSCLC  2/3L Bladder aPDL1+Tarceva aCD20/CD3 biMAb aPDL1+Avastin aPDL1+Avastin+chemo NSCLC Solid tumors 1L Renal 1L non sq NSCLC aPDL1+Zelboraf aPDL1+ipilimumab aPDL1 aPDL1+chemo Melanoma Solid tumors 1/2L Bladder  1L non sq NSCLC aPDL1+Cotellic aPDL1+IFN-alfa aPDL1+chemo Solid tumors Solid tumors 1L sq NSCLC aPDL1+Avastin aPDL1+aCD40 aPDL1 Solid tumors Solid tumors 1L non sq NSCLC (Dx+) aPDL1+Gazyva aPDL1+aOX40 aPDL1 R/R FL / aNHL Solid tumors 1L sq NSCLC (Dx+) aPDL1+Avastin+chemo aPDL1+aCSF-1R aPDL1+chemo Solid tumors Solid tumors 1L TNBC aPDL1+lenalidomide aPDL1+aCEA-IL2v FP aPDL1+Avastin MM Solid tumors 1L RCC aPDL1+Zelboraf+Cotellic aPDL1+IDO aPDL1 Melanoma Solid tumors Adjuvant MIBC (Dx+) aPDL1+alectinib aPDL1 ALK+ NSCLC Adjuvant NSCLC (Dx+) aPDL1+/-azacitidine MDS aPDL1 trials aCEA-IL2v FP NME monotherapy Solid tumors  aOX40 Immune doublets Solid tumors Additions in 2015 aCEA/CD3 TCB Data at ECC 2015 Solid tumors  26 Status as of Oct 22, 2015 POPLAR/BIRCH: OS benefit in 2/3L NSCLC Filing in early 2016 on track

POPLAR • Improved OS correlates with PD-L1 expression • Likelihood of survival doubled in PD-L1 high • Majority of responses still ongoing: 57%

BIRCH • ORR met for all subgroups (1L/2L/3L+) • ORR similar to POPLAR • 6-month OS rate consistent with POPLAR

OS=overall survival; NE=not estimable; a=unstratified HR for subgroups and stratified HR for ITT; 27 Data cut-off POPLAR May 8, 2015. Data cutoff BIRCH May 28, 2015 IMvigor 210: New standard of care in bladder Filing in early 2016 on track

IC2/3 IC0/1 All n = 100 n = 211 n = 311 6 mo-OS, % 70% 56% 60% Median OS, mo NR 6.7 7.9 Median PFS, mo 2.1 2.1 2.1 ORR, % 27% 10% 15% CR, % 8% 2% 4%

IMvigor 210 • Response rates and 6-month OS correlate with PD-L1 status • OS data immature: Median OS in IC2/3 patients not yet reached • Durable responses with median DOR not reached in any subgroup • Well tolerated with superior safety profile over chemotherapy

OS=overall survival; IC=immune cells; PFS=progression free survival; ORR=overall response rate; CR=complete response; 28 NR=not reached; Data cutoff May 5, 2015. Follow up ≥ 24 weeks. Ocrelizumab: First drug active in both RMS & PPMS Results confirm central role of B cells in MS

Targeted product profile • Humanised anti-CD20 antibody • Selective depletion of a B cell subset leaving the ability to generate new B cells intact • Administered IV twice yearly

RMS=relapsing forms of multiple sclerosis (MS) which includes patients with RRMS and SPMS with superimposed relapses; RRMS=relapsing-remitting MS; SPMS=secondary progressive MS; PPMS=primary progressive MS; 29 Adapted from Lublin 1996, Arnold 2004 OPERA I/II: Positive results in RMS Superior efficacy, similar safety to Rebif®

Relative Risk Reduction ® Study Endpoint versus Rebif OPERA I OPERA II POOLED 1 EP ARR -46% -47% NA CDP (12 wks) -43% -37% -40% CDP (24 wks) -43% -37% -40% Key T1 Gd-enhancing -94% -95% NA 2 EP lesions New and/or -77% -83% NA enlarging T2 lesions

OPERA I/II • Ocrelizumab superior to Rebif® (interferon beta-1a) in substantially reducing the three major markers of disease activity: – Annualized relapse rate – Confirmed Disability Progression for both 12 and 24 weeks – MRI outcomes of brain inflammation and damage • Similar safety to interferon beta-1a over the two-year controlled treatment period

RMS=relapsing forms of multiple sclerosis; ARR=annualized relapse rate; CDP=confirmed disability progression; MRI=magnetic resonance imaging; IFN=interferon; *Adjusted ARR calculated by negative binomial regression and adjusted for baseline EDSS score (<4.0 vs ≥4.0), and geographic region 30 (US vs ROW); EDSS=expanded disability status scale Range of treatment options in RMS Varying efficacy and safety profiles

ILLUSTRATIVE

More

Alemtuzumab Natalizumab Natalizumab Unmet Need

(JCV+) (JCV-)

Daclizumab

Dimethyl

Fingolimod fumarate EFFICACY

Teriflunomide Injectable ABCRs Oral (Interferons and Copaxon) Less Less / Later SAFETY/ USE More / Earlier

Source: Adapted from Hauser SL, et al. Ann. Neurol. 2013;74(3):317-327 31 RMS=relapsing forms of multiple sclerosis; ABCR=Avonex®; Betaseron®; Copaxon®; Rebif® ORATORIO: Positive results in PPMS First positive efficacy outcome

Relative Risk Reduction Study Endpoint versus placebo ORATORIO 1 EP CDP (12 wks) 24% CDP (24 wks) 25% Timed 25-foot walk 29% (baseline to wk 120) Key T2 lesion volume 2 EP 3.4% (baseline to wk 120) Whole brain volume 17.5% (wk 24 to wk 120)

ORATORIO • Data establishes role of B cells in PPMS • Significant risk reductions on primary and key secondary endpoints • Favourable safety profile: Serious infections similar to placebo during a mean treatment duration of 3 years

PPMS=primary progressive multiple sclerosis; CDP=confirmed disability progression 32 YTD Sept 2015 sales

Innovation

Outlook

33 2015: Key late-stage news flow

Compound Indication Milestone Avastin Cervical cancer EU approval  Lucentis Diabetic retinopathy US approval Regulatory  alectinib 2L ALK+ NSCLC US/EU filing  cobimetinib + Zelboraf 1L Melanoma US/EU approval Gazyva MabThera/Rituxan-refractory iNHL Ph III GADOLIN  Gazyva Front-line aNHL Ph III GOYA (interim) 2016 ocrelizumab Relapsing forms of MS (RMS) Ph III OPERA I/II  Phase III readouts* ocrelizumab Primary progressive MS (PPMS) Ph III ORATORIO  Perjeta 2L HER2+ mBC Ph III PHEREXA Kadcyla 2L HER2+ gastric cancer Ph II/III GATSBY  atezolizumab** 2/3L Bladder Ph III  atezolizumab** 1L TNBC Ph III  atezolizumab** 1L RCC Ph III  Phase III starts atezolizumab** Adjuvant bladder Ph III  etrolizumab Crohn`s disease Ph III  ACE910 Hemophilia A Ph III taselisib (PI3K inhib) HR+/PI3Kmut BC Ph III SANDPIPER  atezolizumab 2/3L NSCLC Ph II FIR, POPLAR, BIRCH  Phase II readouts* atezolizumab Bladder Ph II  ipatasertib (AKT inhib) Gastric/prostate cancers Ph II A.MARTIN, JAGUAR

* Outcome studies are event driven, timelines may change; ** For atezolizumab (aPDL1) only P3 trials in new indications are 34 listed (1L NSCLC starts not shown) Pharma: Making a difference for patients Significant opportunities ahead

Year Molecule Indication Trial name Event Alectinib ALK+ NSCLC AF-002JG, ACCALIA NME filed 2015 Cotellic+Zelboraf BRAFV600 melanoma coBRIM NME filed Venetoclax 17p del R/R CLL NME filing Atezolizumab 2/3L NSCLC, bladder BIRCH, POPLAR, Imvigor 210 NME filing Ocrelizumab RMS, PPMS OPERA I/II, ORATORIO NME filing 2016 Lebrikizumab Asthma LAVOLTA I/II, ACOUSTICS Pivotal data Perjeta+Herceptin Adjuvant HER2+ breast APHINITY Pivotal data Gazyva Front-line aNHL GOYA Pivotal data ACE 910 Hemophila A Pivotal data Lampalizumab Geographic atrophy CHROMA, SPECTRI Pivotal data 2017 Gazyva 1L iNHL GALLIUM Pivotal data Atezolizumab+chemo 1L NSCLC IMpower 110/150/130/111/131 Pivotal data

Oncology Neuroscience Ophthalmology Immunology

Timelines may change as trials can be event-driven NME=new molecular entity; NSCLC=non-small cell lung cancer; CLL=chronic lymphoid leukemia; RMS=relapsing multiple sclerosis 35 (MS); PPMS=primary progressive MS; aNHL=aggressive non-hodgkin`s lymphoma; iNHL=indolent non-hodgkin`s lymphoma Newsflow in H2 2015

Vienna, 25 -29 Sep  Barcelona, 7-10 Oct  San Francisco, 18-21 Nov • atezolizumab (+chemo) • ocrelizumab • atezolizumab + Zelboraf - NSCLC: POPLAR , BIRCH, - RMS: P3 OPERA I/II - mM: P1 P1b chemo combo update - PPMS: P3 ORATORIO • Cotellic + Zelboraf - Bladder: P2 (2L cohort) - BRAF+mM: coBRIM OS data • alectinib - ALK+ NSCLC: P2 update • CEA-IL2v FP; IDOi - solid tumors: P1 updates

San Antonio, 19-22 Nov Orlando, 5-8 Dec San Antonio, 8-12 Dec • atezolizumab • venetoclax • Atezolizumab + chemo - GBM: P1 - R/R CLL: P2 - TNBC: P1b abraxane combo • venetoclax combinations - AML: P1 + chemo - CLL: P1 + Rituxan+benda - CLL: P1 + Gazyva • Gazyva + chemo - NHL: P3 GADOLIN update - CLL: P3 GREEN update 36 Presentations planned Diagnostics Division Roland Diggelmann COO Roche Diagnostics

37 YTD September 2015: Diagnostics sales Strong sales performance

2015 2014 Change in % CHFm CHFm CHF CER Diagnostics Division 7,835 7,792 1 6 Professional Diagnostics 4,487 4,397 2 7 Diabetes Care 1,533 1,721 -11 -3 Molecular Diagnostics 1,248 1,165 7 10 Tissue Diagnostics 567 509 11 12

Underlying growth of Molecular Diagnostics excluding Sequencing business: +7% 38 CER=constant exchange rates YTD September 2015: Diagnostics regional sales Growth driven by APAC and EMEA

Japan North America -5% +2% EMEA1 4% of divisional sales 26% of divisional sales +4% 43% of divisional sales

Asia Pacific Latin America +15% +13% 20% of divisional sales 7% of divisional sales

16% growth in E7 countries2

1Europe, Middle East and Africa; 2Brazil, China, India, Mexico, Russia, South Korea, Turkey 39 All growth rates at constant exchange rates YTD September 2015: Diagnostics Division Growth driven by Professional Diagnostics

YoY CER growth

Growth driven by immunodiagnostics Professional +7% • Dia (+12%) and coagulation monitoring (+10%)

• Accu-Chek Aviva/Performa (-1%) and Diabetes -3% Care insulin delivering systems (+8%)

Molecular 1 +10% • Virology (+13%) incl. HPV (+24%) Dia

EMEA Tissue +12% Dia North America • Advanced staining portfolio (+12%) RoW

CHFbn 0 1 2 3 4 5

1 Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +7% 40 CER=constant exchange rates; EMEA=Europe, Middle East and Africa Immunoassays: 28% of Diagnostics sales Growing double digit (+12%)

Sales

+13% +8% +10% +12% YoY CER growth

+13%

+21%

+30% +9%

+11%

Tumormarker Endo - Cardiac Women's Infectious Other Critical Care Anemia Hormones Thyroid Health Diseases

CER=constant exchange rates; “Other” include Needed Common Products, Allergy, Rheumatoid Arthritis, Immunosuppressants 41 Launch of cobas® c 513 for diabetes testing* Double throughput with the same footprint

High throughput HbA1c** testing: Risk identification, diagnosis and monitoring • 5 times faster than closest competitor • Highest result reliability • Highest test capacity allows for most efficient workflow and hands-off time cobas ® c 513 • Target market: ~CHF 520m (+5%)***

* Available for countries accepting CE mark approval; **HbA1c: glycated hemoglobin is a marker used for diabetes testing 42 *** market growth for 2014 and CAGR for 2014-19 Point of Care Molecular Diagnostics CLIA waiver for cobas Liat Flu A/B test

• Fast readout and easy-to-use Liat™ tube • Plans to extend menu in: – RSV tests – MRSA and C-difficile • Target market: ~CHF 350m (+20%)

Liat™ Analyzer

Point of Care: e.g. physician’s office, emergency rooms, health clinics, pharmacies; MRSA=methicillin resistant staphylococcus aureus; 43 RSV=respiratory cyntical virus Launch of EGFR liquid biopsy and tissue test Potential to detect tumor progression in NSCLC

Patient example

SQI*

Treatment Clinical Re-appearance initiation Progression of tumor mutations

Detection of tumor mutations may aid in the management of NSCLC patients

*SQI (semi-quantitative index) reflects a trend in the cell free tumor DNA quantity. Upon TKI treatment, we see a decline in tumor 44 mutations (L858R and T790M), in a background of non-tumor DNA (cfDNA_WT); Sorenson et al Cancer 2014;120:3896-901

Key launches 2015

Area Product Market BA1 cobas c 513 – dedicated HbA1C analyzer EU  RPD cobas t 411– core lab coagulation analyzer EU RPD Laboratory cobas 8100 V2 – Integrated pre- and post-analytical solution WW  RPD ® Instruments cobas 6800/8800 – Medium to High volume automated real-time PCR US  RMD / VENTANA HE 600 – automated H&E staining platform WW RTD Devices Accu-Chek Active no-code– next-gen. bG meter, no coding of test strips Diabetes WW  RDC – bG meter with connectivity to smartphones, mobile Care Accu-Chek Connect US RDC applications and cloud  Point of Care CoaguChek® Pro II - professional system for PT and aPTT testing EU RPD Blood cobas® 6800/8800 MPX – Multiplex Bloodscreening test US RMD Screening Infectious cobas® Liat Influenza A/B + RSV – POC detection US RMD Diseases HTLV– human T-lymphotropic virus diagnostics test EU  RPD ® Tests cobas 6800/8800 HBV – Quantitative HBV viral load test EU  RMD / cobas® 4800 HIV-1 - Quantitative HIV viral load test EU RMD Virology Assays cobas® 4800 HCV – Quantitative HCV viral load test EU RMD cobas® 4800 HBV – Quantitative HBV viral load test EU RMD Genomics & cobas® EGFR Test v2 - detection of EGFR in plasma EU RMD Oncology  Cardiac cobas h 232 Troponin T – Point of Care test version of Elecsys cTNT-hs EU  RPD

1 Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics; 45 RTD: Roche Tissue Diagnostics Finance Alan Hippe Chief Financial Officer

46 Q3 2015: Highlights

Sales

• Strong underlying sales growth in all regions and both divisions

Guidance for FY 2015 • Upgraded

Q3 debt restructuring • Bond maturity – USD: 1.0bn maturity on 15 July 2015 - coupon 4.75% s.a. • Bond tender offer results – USD: 337m of 1.6bn outstanding – coupon 7.00% s.a. Notes due 2039 (RHI) – USD: 543m of 2.0bn outstanding – coupon 6.00% s.a. Notes due 2019 (RHI) – USD: 25m of 350m outstanding – coupon 5.25% s.a. Senior Notes due 2035 (Genentech)

s.a.=semi-annual coupon; RHI = Roche Holdings, Inc. (USA) 47

Exchange rate impact on sales growth Negative impact from EUR, LATAM and Europe more than offsetting positive impact of USD

+2.6p +0.1p -0.2p -0.8p -1.0p

-1.3p

-2.9p

CER 5.7% CHF sales sales growth growth YTD Sep 15 2.2% YTD Sep 15 vs. vs. YTD Sep 14 YTD Sep 14 CER USD As-Pac Other JPY Other LATAM EUR CHF Europe CER=constant exchange rates 48 Negative currency impact in 2015 expected

CHF / USD Assumed average YTD 2015 0.95 0.96 0.95 0.95

5% 6% Average 7% 6% YTD 2014 +1% 0.91 Assuming the 30 Sept 2015 exchange +1% 0.90 0.89 0.89 rates remain stable until end of 2015, 0.95 0.93 0.98 0.96 0.93 0.93 0.95 0.97 0.97 0.97 0.97 0.97 2015 impact is expected to be (%p): Monthly avg fx rates 2015 Fx rates at 30 Sep 2015 J F M A M J J A S O N D Q1 HY Sept FY YTD

CHF / EUR Sales -2 -3 -4 -4 1.22 1.22 1.22 1.21 Core operating -4 -6 profit -12% -13% -13% -12% +2%1.08 +2% 1.06 1.07 Core EPS -7 -9 1.06

1.10 1.06 1.06 1.04 1.04 1.05 1.05 1.08 1.09 1.09 1.09 1.09

J F M A M J J A S O N D

49 2015 outlook: Guidance upgraded

Group sales growth1 Mid-single digit

Core EPS growth1 Ahead of sales growth2

Dividend outlook Further increase dividend in Swiss francs

1 At constant exchange rates (CER) 50 2 Excluding sale of filgrastim rights in 2014 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 51 Changes to the development pipeline Q3 2015 update

New to Phase I New to Phase II New to Phase III New to Registration 5 NMEs transitioned from Ph0 1 NME transitioned from Ph1 1 NME transitioned from Ph2 RG6024 anti-FluB MAb – influenza B RG7716 VEGF/ANG2 MAb - wAMD following EU & US submissions RG6029 Nav1.7 inh (2) – pain 1 AI transitioned from Ph1 RG7853 alectinib – ALK+ NSCLC 2L RG7386 FAP-DR5 biMAb – solid tumors RG3645 ranibizumab port delivery 1 AI transitioned from Ph3 RG7828 CD20/CD3 biMAb – hem tumors system (PDS) - wAMD following EU & US submissions RG7986 ADC – r/r NHL 1 AI RG7159 Gazyva – iNHL rituximab- 1 NME in collaboration with ISIS RG3637 lebrikizumab – COPD refractory ISIS antisense oligonucleotide (ASO) – 1 AI added by Chugai Huntington’s Disease nemolizumab (IL-31) MAb - pruritus 1 NME added by Chugai in dialysis patients CHU - hyperphosphatemia

Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration

1 NME 1 NME 1 AI (filing no go decision) 1 AI following EU approval RG7345 Tau MAb – Alzheimer’s disease RG1678 bitopertin – obsessive RG435 Avastin – ovarian ca. 1L RG1273 Perjeta – HER2+ BC neoadj compulsive disorders 1 NME returned to partner RG1577 sembragiline - Alzheimer’s disease

Status as of October 22, 2015 52 Roche Group development pipeline Phase I Phase II (35 NMEs + 13 AIs) (20 NMEs + 14 Als)

RG6016 LSD1 inh AML RG6069 - fibrosis RG3502 Kadcyla HER2+ NSCLC RG6047 SERD (2) ER+(HER2-neg) mBC RG7625 Cat-S antag autoimmune diseases RG6013 FIXa/FX biMAb hemophilia A RG6061 HIF1 alpha LNA solid tumors RG7880 - inflammatory diseases RG6046 SERD ER+(HER2-neg) mBC RG6078 IDO inh solid tumors RG6024 Flu B MAb influenza B RG7155 emactuzumab PVNS/solid tumors RG6078 IDO inh + atezolizumab solid tumors RG6080 DBO β-lactamase inh bact. infections RG7221 vanucizumab mCRC RG7116 lumretuzumab mBC RG7689 - infectious diseases RG7421 cobimetinib+paclitaxel TNBC RG7155 emactuzumab + atezolizumab s. tumors RG7944 therapeutic vaccine HBV RG7440 ipatasertib solid tumors RG7304 Raf & MEK dual inh solid tumors RG6029 Nav1.7 inh (2) pain RG7446 atezolizumab NSCLC 2/3L RG7386 FAP-DR5 biMAb solid tumors RG7893 Nav1.7 inh pain RG7446 atezolizumab bladder cancer 1/2L RCC RG7388 idasanutlin solid & heme tumors RG7800 SMN2 splicer spinal muscular atrophy RG7596 polatuzumab vedotin heme tumors RG7446 atezolizumab solid tumors RG7935 a-synuclein MAb Parkinson's Disease ADCRG7599 lifastuzumab vedotin Pt-resist. OC RG7446 atezo+Zelboraf+/-cobi m. melanoma ISIS ASO Huntington’s Disease RG7601 venetoclax 17p del CLL rel/ref RG7446 atezo+Avastin+chemo solid tumors CHU PTH1 recep. ago hypoparathyroidism RG7601 venetoclax DLBCL RG7446 atezolizumab+cobimetinib solid tumors PT CHU - hyperphosphatemia RG7601 venetoclax+Rituxan FL rel/ref RG7446 atezolizumab+ipi/IFN solid tumors RG7604 taselisib NSCLC sq 2L RG7446 atezo+Tarceva /alectinib NSCLC RG7604 taselisib ER+(HER2-neg) BC neoadj RG7446 atezolizumab+Gazyva lymphoma RG7686 codrituzumab (glypican-3) liver cancer RG7446 atezo+lenalidomide multiple myeloma RG1569 Actemra systemic sclerosis RG7450 anti-Steap 1 ADC prostate ca. RG3637 lebrikizumab +/- Esbriet IPF RG7597 duligotuzumab + cobi solid tumors New Molecular Entity (NME) RG3637 lebrikizumab atopic dermatitis RG7601 venetoclax heme indications Additional Indication (AI) RG3637 lebrikizumab COPD RG7601 venetoclax+Gazyva CLL CHU nemolizumab (IL-31) atopic dermatitis Oncology RG7741 ChK1 inh solid tum & lymphoma CHU nemolizumab (IL-31) pruritus dialysis pts Immunology RG7775 MDM2 (4) IV prodrug AML Infectious Diseases RG7227 danoprevir HCV RG7802 CEA CD3 TCB solid tumors CardioMetabolism RG7745 Flu A MAb influenza A Neuroscience RG7813 CEA IL2v FP+atezolizumab solid tumors RG7795 TLR7 agonist HBV Ophthalmology RG7828 CD20/CD3 biMAb heme tumors Other CHU URAT1 inh gout RG7841 anti-Ly6E ADC solid tumors RG1662 basmisanil Down Syndrome RG7842 ERK inh + cobimetinib solid tumors RG-No Roche Genentech managed RG7929RG6083 olesoxime spinal muscular atrophy CHU Chugai managed RG7876 CD40 iMAb+atezolizumab solid tumors RG7090 basimglurant TRD ISIS ISIS managed RG7882 ADC ovarian ca RG7314 V1 receptor antag autism RG7888 OX40 MAb solid tumors RG7412 crenezumab Alzheimer’s RG7888 OX40 MAb + atezolizumab solid tumors CLL RG3645 ranibizumab PDS wAMD 53 RG7986 ADC r/r NHL RG7716 VEGF-ANG2 biMAb wAMD Status as of October 22, 2015 Roche Group development pipeline

Phase III Registration (8 NMEs + 30 Als) (2 NMEs + 3 Als) RG435 Avastin glioblastoma 1L RG105 MabThera pemphigus vulgaris RG105 MabThera SC CLL RG435 1 Avastin rel. ovarian ca. Pt-sensitive RG1569 Actemra giant cell arteritis RG435 2 Avastin+Tarceva EGFR mut+ NSCLC RG1273 Perjeta+Herceptin HER2+ mBC 2L RG3637 lebrikizumab severe asthma RG7159 Gazyva iNHL rituximab-refractory RG1273 Perjeta+Herceptin HER2+ BC adj RG7413 etrolizumab ulcerative colitis RG7421 3 cobimetinib+Zelboraf m. melanoma RG1273 Perjeta+Herceptin HER2+gastric ca 1L RG7413 etrolizumab Crohn’s disease RG7853 alectinib ALK+ NSCLC 2L RG3502 Kadcyla HER2+ gastric cancer 2L CHU Actemra large-vessel vasculitis RG3502 Kadcyla HER2+ BC adj CHU IL-6R MAb neuromyelitis optica RG3502 Kadcyla + Perjeta HER2+ BC adj RG1450 gantenerumab Alzheimer’s 1 US only: FDA submission pending 2 EU only RG3502 Kadcyla + Perjeta HER2+ BC neoadj RG1594 ocrelizumab RMS 3 Positive CHMP opinion EU Sept 2015 RG7159 Gazyva DLBCL1L RG1594 ocrelizumab PPMS RG7159 Gazyva follicular lymphoma 1L RG7417 lampalizumab geographic atrophy RG7204 Zelboraf melanoma adj RG7446 atezolizumab NSCLC 2L RG7446 atezolizumab+chemo NSCLC non-sq. 1L 1L NSC RG7446 atezo+chemo+Avastin NSCLC non-sq. 1L RG7446 atezolizumab+chemo NSCLC sq. 1L New Molecular Entity (NME) RG7446 atezolizumab Dx+ NSCLC sq. 1L Additional Indication (AI) RG7446 atezolizumab Dx+ NSCLC non-sq. 1L Oncology RG7446 atezolizumab Dx+ NSCLC adj Immunology RG7446 atezolizumab+abraxane TNBC Infectious Diseases CardioMetabolism RG7446 atezolizumab+Avastin RCC Neuroscience RG7446 atezolizumab bladder cancer 2L Ophthalmology RG7446 atezolizumab muscle inv. bladder ca adj Other RG7601 venetoclax+Rituxan CLL rel/ref RG-No Roche Genentech managed RG7601 venetoclax+Gazyva CLL 1L CHU Chugai managed RG7604 taselisib ER+(HER2-neg) mBC ISIS ISIS managed RG7853 alectinib ALK+ NSCLC 1L RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU RG7159 Gazyva is branded as Gazyvaro in EU

Status as of October 22, 2015 54 NME submissions and their additional indications Projects currently in phase 2 and 3 basmisanil GABRA5 NAM Down syndrome

atezolizumab (RG7446) V1 receptor antag (RG7314) + abraxane TNBC autism

taselisib ( RG7604) atezolizumab (RG7446) crenezumab (RG7412) NSCLC sq 2L NSCLC adj (Dx+) Alzheimer‘s

taselisib ( RG7604) New Molecular Entity atezolizumab (RG7446) gantenerumab (RG1450) ER+(HER2-neg) BC neoadj MIBC adj Alzheimer‘s Oncology Immunology SERD (RG6046) atezolizumab(RG7446) lebrikizumab (RG3637) Infectious Diseases ER+(HER2-neg) mBC NSCLC sq 1L (Dx+) COPD CardioMetabolism Neuroscience emactuzumab (RG7155) atezolizumab(RG7446) lebrikizumab (RG3637) Ophthalmology PVNS and solid tumors NSCLC non-sq 1L (Dx+) atopic dermatitis Other vanucizumab (RG7221) atezolizumab(RG7446)+ lebrikizumab+/-Esbriet colorectal cancer chemo NSCLC sq 1L (RG3637) IPF

ipatasertib atezolizumab(RG7446)+ etrolizumab (RG7413) (RG7440) solid tumors chemo NSCLC non-sq 1L Crohn’s disease

ocrelizumab (RG1594) olesoxime (RG6083) polatuzumab vedotin (RG7596) atezolizumab(RG7446)+chemo etrolizumab (RG7413) PPMS SMA heme tumors + Avastin NSCLC non-sq 1L ulcerative colitis

ocrelizumab (RG1594) venetoclax+rituxan lifastuzumab (RG7599) cobimetinib+paclitaxel TLR7 ago (RG7795) RMS (RG7601) CLL rel/refractory Pt resistant OC TNBC HBV

lebrikizumab (RG3637) alectinib (RG7853) taselisib (RG7604) venetoclax (RG7601) danoprevir* (RG7227) severe asthma Alk+ NSCLC 1L HER2 neg ER+ mBC + Rituxan FL rel/ref HCV

venetoclax (RG7601) atezolizumab (RG7446) atezolizumab(RG7446) codrituzumab (RG7686) venetoclax (RG7601) Flu A MAb (RG7745) 17p del CLL rel/ref bladder cancer combo Avastin RCC liver cancer + Gazyva CLL 1L influenza alectinib (RG7853)(US) atezolizumab(RG7446) FIXa /FX biMAb lampalizumab (RG7417) venetoclax (RG7601) VEGF/ANG2 biMAb(RG7716) Alk+ NSCLC 2L  NSCLC 2/3L (RG6013) hemophilia A geographic atrophy DLBCL wAMD 2015 2016 2017 2018 and beyond Unless stated otherwise, submissions are planned to occur in US and EU 55 * lead market China Status as of October 22, 2015 Submissions of additional indications for existing products Projects currently in phase 2 and 3

Kadcyla HER2-pos. NSCLC

*Avastin (US) Kadcyla+Perjeta rel. ovarian ca. Pt-sens. HER2-pos. BC neoadj.

Kadcyla Kadcyla+Perjeta HER2-pos. gastric cancer 2L HER2-pos. BC adj.

Gazyva Kadcyla DLBCL 1L HER2-pos. BC adj.

Gazyva Perjeta + Herceptin Zelboraf MabThera iNHL rituximab-ref.  HER2-pos. mBC 2L melanoma adj. pemphigus vulgaris Avastin +Tarceva (EU) Perjeta + Heceptin Gazyva Actemra EGFR mut+ NSCLC  HER2-pos. BC adj. follicular lymphoma 1L systemic sclerosis Avastin (US) Actemra Perjeta+Herceptin ranibizumab PDS (US) GBM giant cell arteritis HER2-pos. gastric cancer 1L wAMD 2015 2016 2017 2018 and beyond

*approved in EU Oncology Neuroscience Unless stated otherwise, submissions are planned to occur in US and EU. Immunology Ophthalmology Infectious Diseases Other CardioMetabolism NME

Status as of October 22, 2015 56 Major granted and pending approvals 2015

Approved Pending approvals

alectinib ALK+ NSCLC 2L Filed July 2015

Lucentis cobimetinib + Zelboraf Gazyva US diabetic retinopathy m. melanoma iNHL rituximab-ref. February 2015 Filed December 2014 Filed August 2015

Avastin alectinib Avastin + Tarceva cervical cancer ALK+ NSCLC 2L EGFR mut+ NSCLC EU April 2015 Filed September 2015 Filed July 2015

Perjeta *cobimetinib + Zelboraf MabThera SC HER2+ BC neoadj. m. melanoma CLL July 2015 Filed September 2014 Filed November 2014

Gazyva iNHL rituximab-ref. Filed September 2015

Xeloda Bonviva Japan-Chugai gastric cancer adj. osteoporosis (oral) Filed December 2014 Filed February 2015

Avastin cervical cancer Filed September 2015

Oncology Neuroscience Immunology Ophthalmology Infectious Diseases Other

CardioMetabolism NME Status as of October 22, 2015 * Positive CHMP opinion EU 57 Sep 2015 Cancer immunotherapy pipeline overview

Phase I Phase II Phase III (6 NMEs + 13 AIs) (1 NME + 2 Als) (1 NME + 10 AIs)

RG6078 IDO inh solid tumors RG7155 emactuzumab PVNS/solid tumors RG7446 atezolizumab NSCLC 2L RG6078 IDO inh+atezolizumab solid tumors RG7446 atezolizumab NSCLC 2/3L RG7446 atezo+chemo NSCLC non-sq. 1L RG7155 emactuzumab+atezolizumab s.tumors RG7446 atezolizumab bladder cancer 1/2L RCC NSC RG7446 atezo+chemo+Avastin NSCLC non-sq. 1L RG7446 atezolizumab solid tumors RG7446 atezolizumab+chemo NSCLC sq. 1L RG7446 atezo+Zelboraf+/-cobimetinib m. melanoma RG7446 atezolizumab Dx+ NSCLC sq. 1L RG7446 atezo+Avastin+chemo solid tumors RG7446 atezolizumab Dx+ NSCLC non-sq. 1L RG7446 atezolizumab+cobimetinib solid tum RG7446 atezolizumab bladder cancer 2L RG7446 atezolizumab+ipi/IFN solid tumors RG7446 atezolizumab Dx+ NSCLC adj RG7446 atezo+Tarceva NSCLC EGFR+ RG7446 atezolizumab+abraxane TNBC RG7446 atezolizumab+Gazyva lymphoma RG7446 atezolizumab+Avastin RCC RG7446 atezo+lenalidomide multiple myeloma RG7446 atezolizumab muscle inv. bladder ca adj RG7802 CEA CD3 TCB solid tumors RG7813 CEA IL2v FP+atezolizumab solid tumors RG7828 CD20/CD3 biMAb hem tumors RG7876 CD40 iMAb+atezolizumab solid tumors RG7888 OX40 MAb solid tumors RG7888 OX40 MAb + atezolizumab solid tumors *INCB atezolizumab + IDO inh solid tumors New Molecular Entity (NME) *CDX atezolizumab +varlilumab solid tumors Additional Indication (AI)

*external collaborations: INCB- Incyte INCB024360, Oncology CDX-1127- Celldex CD27 MAb RG-No Roche Genentech managed CHU Chugai managed

Status as of October 22, 2015 58 Roche Group development pipeline Combinations

Phase I Phase II Phase III (4 NMEs + 11 AIs) (1 NME + 2 Als) (1 NME + 1 AI)

RG6078 IDO inh+atezolizumab solid tumors RG7421 cobimetinib+paclitaxel TNBC RG435 1 Avastin+Tarceva EGFR mut+ NSCLC RG7155 emactuzumab+atezolizumab s.tum RG7601 venetoclax+Rituxan FL rel/ref RG7421 2 cobimetinib+Zelboraf m. melanoma RG7446 atezo+Zelboraf+/-cobimetinib m. melanoma RG3637 lebrikizumab +/- Esbriet IPF RG7446 atezo+Avastin+chemo solid tumors

RG7446 atezolizumab+cobimetinib solid tum RG7446 atezolizumab+ipi/IFN solid tumors 1 EU only 2 Positive CHMP opinion EU Sept 2015 RG7446 atezo+Tarceva/alectinib NSCLC Phase III RG7446 atezolizumab+Gazyva lymphoma RG7446 atezo+lenalidomide multiple myeloma (12 AIs) RG7597 duligotuzumab+cobi solid tumors

RG7601 venetoclax+Gazyva CLL CLL RG1273 Perjeta+Herceptin HER2+ mBC 2L RG7813 CEA IL2v FP+atezolizumab solid tum RG1273 Perjeta+Herceptin HER2+ BC adj RG7842 ERK inh+cobimetinib solid tumors RG1273 Perjeta+Herceptin HER2+gastric ca 1L RG7876 CD40 iMAb+atezolizumab solid tum RG3502 Kadcyla + Perjeta HER2+ BC adj RG7888 OX40 MAb+atezolizumab solid tum RG3502 Kadcyla + Perjeta HER2+ BC neoadj RG7446 atezo+chemo NSCLC non-sq. 1L NSC RG7446 atezo+chemo+Avastin NSCLC non-sq. 1L RG7446 atezolizumab+chemo NSCLC sq. 1L New Molecular Entity (NME) RG7446 atezolizumab+abraxane TNBC Additional Indication (AI) RG7446 atezolizumab+Avastin RCC Oncology RG7601 venetoclax+Rituxan CLL rel/ref Immunology RG7601 venetoclax+Gazyva CLL 1L RG-No Roche Genentech managed CHU Chugai managed

Status as of October 22, 2015 59 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 60 Avastin Ovarian cancer clinical development programme

Indication Relapsed platinum-sensitive ovarian cancer

Phase III Phase III Phase/study OCEANS GOG-0213

# of patients N=484 N=674

Design . ARM A: Carboplatin, gemcitabine, and . ARM A: carboplatin and paclitaxel concurrent placebo for 6 - 10 cycles, followed . ARM B: carboplatin, paclitaxel and Avastin by placebo alone until disease progression (from cycle 2 onwards for until disease . ARM B: Carboplatin, gemcitabine, and progression). concurrent Avastin for 6 - 10 cycles, followed by Avastin alone until disease progression.

Avastin dose . 15 mg/kg q3 weeks . 15 mg/kg q3 weeks

Primary . Progression-free survival . Overall survival endpoint

Status . Primary endpoint met Q1 2011 . Study showed a 4.9 mo overall survival . EMA approval received Q4 2012 benefit . Final data presented at SGO 2014 . Presented SGO Q1 2015 . Re-evaluate FDA submission in 2016

SGO=Society of Gynecologic Oncology 61 Avastin Brain and breast cancer clinical development programmes

First-line HER2-negative metastatic breast Indication Newly diagnosed glioblastoma cancer

Phase III Phase III Phase/study AVAglio MERiDiAN

# of patients N=920 N=480

Design . ARM A: Concurrent radiation and . ARM A: Paclitaxel + Avastin temozolomide plus placebo; followed by . ARM B: Paclitaxel + Placebo maintenance TMZ plus placebo for 6 cycles; then placebo until disease progression . ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression

Avastin dose . 10 mg/kg q2 weeks or 15 mg/kg q3 weeks . 10 mg/kg q2 weeks

Primary . Progression-free survival . PFS in ITT endpoint . Overall survival . PFS in patients with high plasma VEGF-A

Status . Co-primary endpoint of PFS met Q3 2012 . Co-primary endpoints met Q1 2015 . Overall survival data presented at ASCO 2013 . Data presented at ECC 2015 . Filed in EU Q1 2013 . Negative CHMP opinion Q3 2014 . US filing pending

TMZ=temozolomide 62 ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress Erivedge A novel small molecule inhibitor of the hedgehog signaling pathway

Locally advanced or metastatic Indication Idiopathic pulmonary fibrosis basal cell carcinoma

Phase II Phase/study Phase II STEVIE

# of patients N=1,200 N=129

Design . Single ARM: 150 mg Erivedge orally . ARM A: Erivedge 150mg daily once daily . ARM B: placebo

Primary . Safety: Incidence of adverse events . Change in forced vital capacity (FVC) endpoint

Status . FPI Q2 2011 . FPI pending in anticipation of trial design . Recruitment completed Q3 2014 amendment to incorporate new standard . Interim data presented at SMR 2014 of care Esbriet

In collaboration with Curis; SMR=Society for Melanoma Research 63 Gazyva/Gazyvaro Oncology development programme

Previously untreated or relapsed/refractory Indication Diffuse large B-cell lymphoma (DLBCL) chronic lymphocytic leukemia

Phase III Phase III Phase/study GREEN GOYA

# of patients N=800 N=1,418

Design . Single-arm cohort study: Gazyva alone or in . ARM A: Gazyva 1000mg IV plus CHOP combination with different chemotherapy . ARM B: MabThera/Rituxan plus CHOP regimens (FC, Bendamustin or Clb), investigation of different strategies to reduce IRRs

Primary . Safety in combination with different . Progression-free survival endpoint chemotherapy regimens

Status . FPI Q4 2013 . Recruitment completed Q2 2014 . Initial safety data presented at ASH 2014 . Trial continues after interim analysis in 2015 . Efficacy data to be presented at ASH 2015 . Final data expected in 2016

In collaboration with Biogen 64 CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; ASH=American Society of Hematology Gazyva/Gazyvaro Oncology development programme (continued)

Indolent Front-line indolent Indication non-Hodgkin’s lymphoma non-Hodgkin’s lymphoma MabThera/Rituxan refractory

Phase III Phase III Phase/stud GADOLIN GALLIUM y Induction and maintenance study Induction and maintenance study

# of N=411 N=1,401 patients

Design . ARM A: Gazyva 1000mg IV plus bendamustine . ARM A: Gazyva 1000mg IV plus chemotherapy followed by Gazyva mainteinance followed by Gazyva maintenance . ARM B: bendamustine . ARM B: MabThera/Rituxan plus chemotherapy followed by MabThera/Rituxan maintenance

. Chemotherapy: . For follicular lymphoma: CHOP, CVP or bendamustine . For non-follicular lymphoma: physician’s choice

Primary . Progression-free survival . Progression-free survival endpoint

Status . Trial stopped at interim for efficacy Q1 2015 . Recruitment completed . Data presented at ASCO 2015 . Expect data in 2017 . Filed globally Q3 2015

In collaboration with Biogen 65 CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone Obinutuzumab (GA101, RG7159) Immunology development programme

Indication Lupus Nephritis

Phase/study Phase II

# of patients N=120

Design . ARM A: Gazyva 1000mg IV plus Mycophenolate Mofetil . ARM B: placebo IV plus Mycophenolate Mofetil

Primary . Percentage of participants who achieve Complete Renal endpoint Response (CRR)

Status . Expect FPI Q4 2015

In collaboration with Biogen 66 Kadcyla Evaluating new treatment options in HER2-positive early breast cancer

HER2-positive neoadjuvant HER2-positive early breast Operable HER2-positive early Indication breast cancer cancer high-risk patients breast cancer

Phase III Phase III Phase III Phase/study KRISTINE KATHERINE KAITLIN

# of patients N=444 N=1,484 N=1,850

Design Before surgery patients will . ARM A: Kadcyla 3.6mg/kg q3w . Following surgery and receive 6 cycles of: . ARM B: Herceptin antracycline-based therapy: . ARM A: Herceptin plus Perjeta . ARM A: Herceptin 6mg/kg q3w plus docetaxel plus carboplatin plus Perjeta 420 mg/kg q3w . ARM B: Kadcyla plus Perjeta plus chemo . ARM B: Kadcyla 3.6mg/kg q3w After surgery patients will plus Perjeta 420mg/kg q3w plus receive: chemo . ARM A: Herceptin plus Perjeta . ARM B: Kadcyla plus Perjeta

Primary . Pathologic Complete Response . Invasive disease-free survival . Invasive disease-free survival endpoint (pCR) (IDFS) (IDFS)

Status . Enrollment completed Q2 2015 . FPI Q1 2013 . Enrollment completed Q2 2015 . Data expected in 2016

In collaboration with ImmunoGen, Inc. 67 Kadcyla Evaluating new treatment options in HER2-positive gastric and lung cancer

Previously treated locally HER2-positive advanced (2L+) Indication advanced or metastatic HER2- NSCLC positive gastric cancer

Phase II/III Phase/study Phase II GATSBY

# of patients N=412 N=40

Design . ARM A: Kadcyla 3.6mg/kg q3w . Single-agent Kadcyla 3.6 mg/kg . ARM B: Kadcyla 2.4mg/kg weekly . ARM C: docetaxel or paclitaxel

Primary . Phase II: Dose-finding . Overall response rate and safety endpoint . Phase III: Overall survival

Status . Recruitment completed Q1 2015 . FPI Q4 2014 . Primary endpoint not met Q3 2015

In collaboration with ImmunoGen, Inc. 68 Lucentis Anti-VEGF antibody fragment for treatment of ocular diseases

Indication AMD port delivery device (Ranibizumab Port Delivery System)

Phase II Phase/study LADDER

# of patients N=220

Design . Four arm study: Lucentis monthly intravitreal control vs. 3 Lucentis concentrations delivered via implant

Primary . Time to first refill endpoint

Status . FPI Q3 2015

In collaboration with Forsight and Novartis 69 MabThera/Rituxan Oncology and immunology development programmes

Indication Previously untreated chronic lymphocytic leukemia Moderate to severely active pemphigus vulgaris

Phase Ib SAWYER Phase III Phase/study Subcutaneous study PEMPHIX Study being conducted ex-US

# of N=225 N=124 patients

Design . Two-stage design: . ARM A: Rituxan - Stage 1 (dose-finding, N=55) . ARM B: mycophenolate mofetil

- Stage 2 (N=170): CLL dose confirmation: . ARM A: MabThera IV plus chemotherapy (fludarabine and cyclophosphamide) . ARM B: MabThera 1600mg SC plus chemotherapy (fludarabine and cyclophosphamide)

Primary . Part 1: PK (dose selection) . Proportion of patients who achieve a sustained complete endpoint . Part 2: PK of MabThera IV versus MabThera SC (arm A vs. remission arm B)

Status . Stage 2 data confirmed non-inferior PK and comparable . FPI Q2 2015 safety/efficacy of MabThera 1600mg SC vs. MabThera IV . Presented at ASH 2014 . Filed in EU Q4 2014

Subcutaneous MabThera : applies Enhanze technology, partnered with Halozyme 70 ASH=American Society of Hematology Perjeta First in a new class of HER dimerization inhibitors

Adjuvant HER2-positive breast Indication Neoadjuvant HER2-positive breast cancer cancer

Phase/ Phase II Phase II Phase III study NEOSPHERE TRYPHAENA APHINITY

# of patients N=417 N=225 N=4,803

Design . ARM A: Herceptin plus docetaxel . ARM A: FEC followed by Taxane with . ARM A: Perjeta (840mg loading, 420 . ARM B: Perjeta (840mg loading, 420mg Herceptin and pertuzumab (H+P given q3w) plus Herceptin for 52 weeks plus q3w) plus Herceptin and docetaxel concurrently) chemotherapy (6-8 cycles) . ARM C: Perjeta plus Herceptin . ARM B: FEC followed by Taxane with . ARM B: placebo plus Herceptin (52 . ARM D: Perjeta plus docetaxel Herceptin + pertuzumab (H+P given weeks) plus chemotherapy (6-8 cycles) sequentially) . ARM C: TCH + pertuzumab (H+P given concurrently)

Primary . Pathologic complete response (pCR) . Safety . Invasive disease-free survival (IDFS) endpoint

Status . Positive data presented at SABCS 2010 . Positive safety and efficacy data . Recruitment completed Q3 2013 . Biomarker data presented SABCS 2011 presented at SABCS 2011 . Expect data in 2016 . Survival data presented at ASCO 2015

. FDA approval granted Q3 2013 . Submitted in the EU Q3 2014 . EU approval received Q3 2015

FEC = fluorouracil, epirubicin, and cyclophosphamide; TCH = docetaxel, carboplatin, Herceptin; 71 SABCS=San Antonio Breast Cancer Symposium; ASCO=American Society of Clinical Oncology Perjeta First in a new class of HER dimerization inhibitors (continued)

Second-line HER2-positive Advanced HER2-positive gastric Neoadjuvant/adjuvant HER2- Indication metastatic breast cancer cancer positive breast cancer

Phase/ Phase III Phase III Phase II study PHEREXA JACOB BERENICE

# of patients N=450 N=780 N=400

Design . ARM A: Herceptin plus Xeloda . ARM A: Perjeta (840mg loading, Neoadjuvant treatment: . ARM B: Perjeta plus Herceptin and 420mg q3w) plus Herceptin and . ARM A: ddAC q2w x4 cycles Xeloda chemotherapy followed by weekly paclitaxel for 12 . ARM B: placebo plus Herceptin weeks, with P+H x4 cycles and chemotherapy . ARM B: FEC+P+H x4 cycles followed by docetaxel+P+H x4 cycles

Adjuvant treatment: . P+H q3w to complete 1 year of HER2 therapy . Hormonal and radiation therapy as indicated

Primary . Progression-free survival . Overall survival . Safety endpoint

Status . Recruitment completed Q3 2013 . FPI Q2 2013 . FPI Q3 2014 . Expect data in 2015

ddAC=dose-dense doxorubicin plus cyclophosphamide; FEC = fluorouracil, epirubicin, and cyclophosphamide 72 Zelboraf A selective novel small molecule that inhibits mutant BRAF

Adjuvant therapy in patients with resected cutaneous Indication BRAF mutation positive melanoma

Phase III Phase/study BRIM8

# of patients N=475

Design . 52-week treatment . ARM A: Zelboraf 960mg bid . ARM B: Placebo

Primary . Disease-free survival endpoint

Status . Enrollment completed Q2 2015 . Expect data in 2016

In collaboration with Plexxikon, a member of Daiichi Sankyo Group See also combinations with: cobimetinib (MEK inhibitor) and atezolizumab (PD-L1 MAb) 73 Actemra/RoActemra Interleukin 6 receptor inhibitor

Indication Systemic sclerosis Giant Cell Arteritis

Phase II Phase III Phase III Phase/study faSScinate focuSSced GiACTA Proof-of-concept study # of patients N=86 N=210 N=250 Design Blinded 48-week treatment with weekly Blinded 48-week treatment with weekly Part 1: 52-week blinded period dosing: dosing: . ARM A: Actemra SC 162mg qw + 26 weeks . ARM A: Actemra SC 162mg . ARM A: Actemra SC 162mg prednisone taper . ARM B: Placebo SC . ARM B: Placebo SC . ARM B: Actemra SC 162mg q2w + 26 weeks prednisone taper Open-label weekly dosing at weeks 49 to Open-label weekly dosing at weeks 49 to . ARM C: Placebo+ 26 weeks prednisone taper 96: 96: . ARM D: Placebo+ 52 weeks prednisone taper . Actemra SC 162mg . Actemra SC 162mg Part II: . 104-week open label extension – patients in remission followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw

Primary . Change in modified Rodnan skin score . Change in modified Rodnan skin score . Proportion of patients in sustained remission at endpoint (mRSS) at week 24 (mRSS) at week 48 week 52 . Safety

Status . 48 week data presented at ACR 2014 . Expect FPI Q4 2015 . LPI Q2 2015 . Primary and all key secondary . Data expected in 2016 endpoints showed trend for improved efficacy . Breakthrough designation granted Q1 2015 74 In collaboration with Chugai; ACR=American College of Rheumatology Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 75 Alectinib (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase

Treatment naïve ALK-positive advanced ALK-positive crizotinib-naïve advanced Indication NSCLC NSCLC Phase I/II Phase III Phase/study AF-001JP ALEX Japanese study # of patients N=286 N=70

Design . ARM A: alectinib 600mg BID . Part 1: Dose escalation monotherapy . ARM A: crizotinib 250mg BID . Part 2: Monotherapy, dose selected based on the results of Part 1

Primary . Progression-free survival . Phase I: Determination of recommended endpoint dose . Phase II: Safety and efficacy

Status . FPI Q3 2014 . Results published in Lancet Oncology 2013 Jun;14(7):590-8 . Approved in Japan with brand name ALECENSA July 2014

In collaboration with Chugai 76 Alectinib (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase (continued)

ALK-positive advanced NSCLC after progression on ALK-positive advanced NSCLC after progression on Indication crizotinib treatment crizotinib treatment

Phase I/II Phase I/II Phase/study AF-002JG/NP28761 ACCALIA/NP28673 US study Global study Phase I: N=36 # of patients N=130 Phase II: N=85

Design . Part 1: Dose escalation monotherapy . Part 1: Dose escalation monotherapy . Part 2: Monotherapy, dose selected based on the results . Part 2: Monotherapy, dose selected based on the results of Part 1 of Part 1

Primary . Phase I: Determination of recommended dose . Phase I: Determination of recommended dose endpoint . Phase II: Safety and efficacy . Phase II: Safety and efficacy

Status . Phase I data presented at ECC 2013 . Phase II FPI Q3 2013 . Phase I full cohort including CNS data published in Lancet . Primary analysis positive Q4 2014 Oncology 2014, Sept.15(10):1119-28 . Updated analysis in Q1 2015 . Phase II FPI Q3 2013 . Data presented at ASCO 2015 . Primary analysis positive Q1 2015 . Updated data presented at ECC 2015 . Data presented at ASCO 2015 . Updated data presented at WCLC

. Filed Q3 (US) and Q3 (EU) 2015 . Priority review granted Q3 2015 . Breakthrough therapy designation granted by the FDA June 2013

In collaboration with Chugai ECC=European Cancer Congress; ASCO=American Society of Clinical Oncology 77 WCLC=World Conference on Lung Cancer Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

1L non-squamous NSCLC Indication 1L non-squamous NSCLC 1L non-squamous NSCLC PD-L1-selected patients

Phase III Phase III Phase III Phase/study IMpower 110 IMpower 150 IMpower 130

# of patients N=400 N=1200 N=550

Design . ARM A: atezolizumab . ARM A: atezolizumab + . ARM A: atezolizumab + nab- monotherapy Avastin + paclitaxel + paclitaxel + carboplatin . ARM B: carboplatin or carboplatin . ARM B: nab-paclitaxel + cisplatin + pemetrexed . ARM B: atezolizumab + carboplatin paclitaxel + carboplatin . ARM C: Avastin + paclitaxel + carboplatin

Primary . Progression-free survival . Progression-free survival . Progression-free survival endpoint

Status . FPI Q3 2015 . FPI Q2 2015 . FPI Q1 2015

78 Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Adjuvant NSCLC 1L squamous NSCLC Indication 1L squamous NSCLC PD-L1-selected patients PD-L1-selected patients

Phase III Phase III Phase III Phase/study IMpower 010 IMpower 111 IMpower 131

# of patients 845 N=400 N=1200

Design Following adjuvant cisplatin- . ARM A: atezolizumab . ARM A: atezolizumab + nab- based chemotherapy monotherapy paclitaxel + carboplatin . ARM A: atezolizumab . ARM B: gemcitabine + . ARM B: atezolizumab + . ARM B: best supportive care cisplatin or carboplatin paclitaxel + carboplatin . ARM C: nab-paclitaxel + carboplatin

Primary . Disease-free survival . Progression-free survival . Progression-free survival endpoint

Status . FPI October 2015 . FPI Q2 2015 . FPI Q2 2015

79 Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Locally advanced or Locally advanced or Locally advanced or Metastatic NSCLC Non-small cell lung Indication metastatic NSCLC metastatic NSCLC metastatic NSCLC 2nd line cancer PD-L1 positive PD-L1 positive (2nd/3rd line)

Phase III Phase II Phase II Phase II Phase/study Phase I OAK FIR BIRCH POPLAR

# of patients N=1,225 N=130 N=635 N=287 N=32

Design . ARM A: atezolizumab Single arm study: Single arm study: . ARM A: atezolizumab . atezolizumab plus 1200mg q3w . atezolizumab 1200mg . atezolizumab 1200mg 1200mg q3w Tarceva1 or alectinib . ARM B: docetaxel q3w q3w . ARM B: docetaxel

Primary . Overall survival . Overall response rate . Objective response . Overall survival . Safety endpoint rate

Status . Recruitment . Recruitment . Recruitment . Recruitment . FPI Q1 2014 completed Q2 2015 completed Q2 2014 completed Q4 2014 completed Q2 2014 . FPI in alectinib arm . Readout in 2016 . Data presented at . Primary analysis . Interim data presented Q3 2015 ASCO 2015 presented at ECC at ASCO 2015 2015 . Primary analysis presented at ECC 2015

1Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress 80 Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Adjuvant high risk muscle Indication invasive bladder cancer PD-L1- Locally advanced or metastatic urothelial bladder cancer positive patients Phase III Phase III Phase II Phase/study IMvigor 010 IMvigor 211 IMvigor 210 # of patients N=440 N=767 N=439

Design After cystectomy: Patients who progressed on at least . Cohort 1: Treatment-naive and . ARM A: atezolizumab one platinum-containing regimen will cisplatin-ineligible patients monotherapy receive: . Cohort 2: Patients with disease . ARM B: observation . ARM A: atezolizumab 1200mg q3w progression following or during . ARM B: chemotherapy (vinflunine, platinum-containing treatment paclitaxel or docetaxel)

Primary . Progression-free survival . Overall survival . Objective response rate endpoint

Status . FPI October 2015 . FPI Q1 2015 . Recruitment completed Q1 2015 . Primary analysis presented at ECC 2015

81 ECC=European Cancer Congress Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Previously untreated Indication metastatic triple negative Untreated advanced renal cell carcinoma breast cancer

Phase III Phase III Phase/study Phase II IMpassion 130 IMmotion 151

# of patients N=350 N=550 N=305

Design . ARM A: atezolizumab plus . ARM A: atezolizumab plus . ARM A: atezolizumab plus nab-paclitaxel Avastin Avastin . ARM B: placebo plus nab- . ARM B: sunitinib . ARM B: atezolizumab; paclitaxel following PD: atezolizumab plus Avastin . ARM C: sunitinib; following PD: atezolizumab plus Avastin

Primary . Progression free survival . Progression free survival . Progression free survival endpoint

Status . FPI Q2 2015 . FPI Q2 2015 . Recruitment completed Q1 2015 . Final readout in 2016

82 Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Relapsed/Refractory Myelodysplastic Indication follicular lymphoma Multiple Myeloma Syndrome (MDS) and DLBCL

Phase/study Phase I Phase I Phase I

# of patients N=46 N=46 N=46

Design Stage 1: Safety evaluation . atezolizumab . atezolizumab . atezolizumab plus monotherapy and monotherapy and Gazyva lenalidomide azacitidine combination Stage 2: expansion combination cohorts cohorts . atezolizumab plus Gazyva

Primary . Safety . Safety . Safety endpoint

Status . FPI Q4 2014 . FPI Q3 2015 . FPI Q3 2015

83 Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Indication Solid tumors Solid tumors Solid tumors

Phase/study Phase I Phase I Phase I

# of patients N=225 N=160 N=110

Design . ARM A: atezolizumab + Avastin . Part 1: sequential administration of atezolizumab in combination with . ARM B: atezolizumab + Avastin + atezolizumab and RG7876 (CD40 emactuzumab (CSF-1R MAb) FOLFOX MAb) . Part 1: dose escalation . ARM C: atezolizumab + carboplatin . Part 2: concomitant administration . Part 2: expansion + paclitaxel of atezolizumab and RG7876 (CD40 . ARM D: atezolizumab + MAb) carboplatin+ pemetrexed . Part 3: study drugs schedule in . ARM E: atezolizumab + specific indication per Part 2 carboplatin+ nab-paclitaxel . ARM F: atezolizumab + nab- paclitaxel

Primary . Safety/PK . Safety . Safety endpoint

Status . FPI Q2 2012 . FPI Q4 2014 . FPI Q1 2015 . Chemo combination data in NSCLC presented at ASCO, WCLC and ECC 2015 . Chemo combination with nab- paclitaxel in TNBC to be presented at SABCS 2015

ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress 84 SABCS=San Antonio Breast Cancer Symposium; WCLC=World Conference on Lung Cancer Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Locally advanced or Indication Solid tumors Solid tumors metastatic solid tumors

Phase/study Phase I Phase I Phase I

# of patients N=224 N=360 N=200

Design . atezolizumab in combination . Stage 1: Dose escalation of . ARM A: atezolizumab plus with RG6078 (IDO inhibitor), atezolizumab plus RG7888 ipilimumab dose escalation and expansion (OX40 MAb) . ARM B: atezolizumab plus cohorts . Stage 2: Expansion interferon alpha-2b atezolizumab plus RG7888 (OX40 MAb)

Primary . Safety . Safety . Safety endpoint

Status . FPI Q2 2015 . FPI Q2 2015 . FPI Q3 2014

85 Atezolizumab (PD-L1 MAb, MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Previously untreated metastatic Indication melanoma BRAF mutation Solid Tumors Locally advanced or metastatic solid tumors positive

Phase/study Phase I Phase I Phase I

# of patients N=44 N=90 N=689

Design . Dose-finding study of . ARM A: Dose-finding atezolizumab . Dose escalation study atezolizumab + Zelboraf1 and plus cobimetinib atezolizumab + Zelboraf1 + . ARM B: Dose-expansion cobimetinib (MEK inhibitor)2 atezolizumab plus cobimetinib combinations

Primary . Safety/PK . Safety . Safety/PK endpoint

Status . FPI Q4 2012 . FPI Q4 2013 . FPI Q2 2011 . Initial efficacy data presented at ASCO 2013 . Updated data presented at ECC 2013 . Data from bladder cohort presented at ASCO and ESMO 2014 . Data from TNBC cohort presented at AACR 2015 . Updated lung and bladder data presented at ASCO 2015 . GBM data to be presented at SNO 2015

1Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2Cobimetinib in collaboration with Exelixis ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress; AACR=American Association for Cancer Research; 86 ESMO=European Society for Medical Oncology; SNO Society for Neuro-Oncology Cotellic (RG7421, GDC-0973) Selective small molecule inhibitor of mitogen- activated protein kinase kinase

Previously untreated metastatic melanoma First-line metastatic triple negative breast Indication BRAF mutation positive cancer

Phase III Phase/study Phase II coBRIM

# of patients N=495 N=112

Design . ARM A: Zelboraf1 plus cobimetinib . ARM A: cobimetinib plus paclitaxel . ARM B: Zelboraf1 plus placebo . ARM B: placebo plus paclitaxel

Primary . Progression-free survival . Progression-free survival, safety endpoint

Status . Primary endpoint met Q3 2014 . FPI Q1 2015 . Data presented at ESMO and SMR 2014 . Results published NEJM 2014 Nov 13;371(20):1867-76 . Filed in EU (Q3) and US (Q4) 2014 . Priority review granted Q1 2015 . Updated data presented at ASCO 2015 . Positive CHMP opinion Q3 2014 . OS superiority achieved Q3 2015 . Data to be presented at SMR 2015

In collaboration with Exelixis 1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; ESMO=European Society for Medical Oncology; SMR=Society for Melanoma Research; NEJM=New England Journal of Medicine; 87 ASCO=American Society of Clinical Oncology Cotellic (RG7421, GDC-0973) Selective small molecule inhibitor of mitogen- activated protein kinase kinase (continued)

Previously untreated Locally advanced or Locally advanced or Indication metastatic melanoma metastatic tumors with Solid tumors metastatic tumors BRAF mutation positive mutant KRAS

Phase/study Phase I Phase I Phase I Phase I

# of patients N=90 N=44 N=50 N=142

Design . ARM A: Dose-finding - . Dose-finding study of . Dose finding of . Dose-finding study of cobimetinib plus cobimetinib + cobimetinib plus cobimetinib plus RG78422 atezolizumab (PD-L1 atezolizumab (PD-L1 MAb) duligotuzumab (HER3 (ERK inhibitor) MAb) + Zelboraf1 and MAb/EGFR DAF) . ARM B: Dose- atezolizumab (PD-L1 MAb) expansion - cobimetinib +Zelboraf1 combinations plus atezolizumab (PD- L1 MAb)

Primary . Safety . Safety/PK . Safety . Safety and tolerability endpoint

Status . FPI Q4 2013 . FPI Q4 2012 . FPI Q4 2013 . FPI Q2 2015

In collaboration with Exelixis 88 1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2 RG7842 in collaboration with Array BioPharma Polatuzumab vedotin (RG7596) Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies

Relapsed or Refractory follicular Indication Non-Hodgkin's lymphoma Non-Hodgkin’s lymphoma lymphoma and DLBCL

Phase II Phase Phase Ib/II Phase Ib/II ROMULUS

# of patients N=228 N=104 N=224

Design . ARM A: pinatuzumab vedotin plus . PhIb: dose escalation . PIb: dose escalation Rituxan . ARM B: polatuzumab vedotin plus . PhII: polatuzumab vedotin in . PhII: polatuzumab vedotin + BR vs. BR Rituxan combination with Rituxan or Gazyva . PhII expansion: polatuzumab vedotin . ARM C: polatuzumab vedotin plus and CHP non-randomized +Gazyva non-randomized Gazyva

Primary . Safety and anti-tumor activity . Safety . Safety and response by PET/CT endpoint

Status . Recruitment in arms A&B completed . FPI Q4 2013 . FPI Q4 2014 Q1 2014 . FPI in Gazyva arm C Q1 2015 . Updated data presented at ASCO, ICML and EHA 2015

In collaboration with Seattle Genetics ASCO=American Society of Clinical Oncology; ICML=international conference on malignant lymphoma; EHA=European Hematology Association 89 BR=bendamustine and Rituxan; CHP=Cyclophosphamide, Hydroxydoxorubicin, Prednisone Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor

HER2-negative ER-positive metastatic breast caner patients Neoadjuvant HER2-negative ER- Indication who progressed after aromatase positive breast cancer inhibitor therapy

Phase III Phase II Phase SANDPIPER LORELEI

# of patients N=600 N=330

Design . ARM A: taselisib plus Fulvestrant . ARM A: taselisib plus letrozole . ARM B: placebo plus Fulvestrant . ARM B: placebo plus letozole

Primary . Progression-free survival . Response rate and pCR endpoint

Status . FPI Q2 2015 . FPI Q4 2014

90 Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor

HER2-negative HR-positive PI3KCAmut-pos. 2L squamous Solid tumors and HER2-negative Indicationx locally recurrent or metastatic NSCLC HR-positive breast cancer breast cancer Lung Master Protocol

Phase II Phase Phase I/II Phase I Lung-MAP

# of patients N=320 N=65 N=120

Design . Phase I . taselisib plus docetaxel . taselisib vs. chemo . taselisib . taselisib plus paclitaxel . taselisib plus letrozole or fulvestrant

. Phase II . taselisib (multiple doses) plus letrozole or fulvestrant

Primary . Safety/PK/efficacy . Safety . Progression-free survival endpoint

Status . Recruitment completed Q2 2014 . FPI Q2 2013 . FPI Q2 2014 . Updated data presented at SABCS 2014

SABCS=San Antonio Breast Cancer Symposium 91 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor

Untreated CLL patients with Relapsed or Refractory CLL Indication coexisting medical Relapsed or Refractory CLL with 17p deletion conditions Phase III Phase III Phase/study Phase II CLL14 MURANO

# of patients N=432 N=370 N=100

Design . ARM A: venetoclax plus . ARM A: venetoclax plus . Single-agent venetoclax Gazyva Rituxan . ARM B: chlorambucil plus . ARM B: Rituxan plus Gazyva bendamustine

Primary . Progression-free survival . Progression-free survival . Safety/MTD endpoint

Status . FPI Q4 2014 . Recruitment completed Q3 . Recruitment completed Q2 2015 2014 . Data expected in 2017 . Breakthrough designation granted in Q2 2015 . Efficacy endpoint met . Expect global filing in 2015

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; ASCO=American Society of Clinical Oncology 92 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor (continued)

Relapsed or Refractory Relapsed or Refractory Relapsed or Refractory Indication Relapsed CLL and SLL or previously untreated or previously untreated CLL CLL CLL

Phase/stud Phase II Phase Ib Phase Ib Phase Ib y # of N=40 N=50 N=70 N=74 patients

Design . venetoclax after ibrutinib . Dose-escalation study in . venetoclax in combination . venetoclax in combination therapy combination with with MabThera/Rituxan with Gazyva . venetoclax after idelalisib MabThera/Rituxan and bendamustine therapy

Primary . Overall response rate . Safety/MTD . Safety/MTD . Safety/MTD endpoint

Status . FPI Q3 2014 . Recruitment completed . FPI Q2 2013 . FPI Q1 2014 . Data to be presented at Q1 2015 . Data to be presented at . Data to be presented at ASH 2015 . Data presented at ASCO ASH 2015 ASH 2015 2014 and EHA 2015 . Updated data to be presented at ASH 2015

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; SLL=Small Lymphocytic Lymphoma 93 ASCO=American Society of Clinical Oncology; EHA=European hematology association Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor (continued)

Relapsed or Refractory Relapsed or Refractory Relapsed or Refractory Indication Front-line DLBCL follicular NHL NHL CLL and NHL

Phase II Phase I/II Phase/study Phase I Phase I CONTRALTO CAVALLI # of patients N=156 N=230 N=40 N=211

Design . ARM A: venetoclax plus Dose finding: . Dose escalation of . Dose-escalation study Rituxan . ARM A: venetoclax+R- venetoclax in combination . ARM B: venetoclax plus CHOP with Rituxan and Rituxan plus bendamustine . ARM B: venetoclax+G- bendamustine . ARM C: Rituxan plus CHOP bendamustine Expansion: . venetoclax+R/G-CHOP

Primary . Overall response rate . Safety and efficacy . Overall response rate . Safety/PK/Response rate endpoint

Status . FPI Q4 2014 . FPI Q2 2014 . FPI Q2 2012 . FPI Q2 2011 . Study resumed Q3 2013 . Updated CLL, SLL and NHL . Data presented at ASCO (DLBCL and FL) data 2015 presented at ASCO 2014 . Updated data to be . Updated data to be presented at ASH 2015 presented at ASH 2015

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma; CLL=Chronic Lymphocytic Leukemia 94 ASCO=American Society of Clinical Oncology Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor (continued)

Indication Relapsed or refractory multiple myeloma Acute myelogenous leukemia (AML)

Phase/study Phase I Phase I Phase II Phase Ib

# of patients N=30 N=30 N=54 N=89

Design . Patients receiving . Dose escalation cohort . Dose escalation of . venetoclax (dose Bortezomib and . Safety expansion cohort venetoclax escalation) +decitabine Dexamethasone as . venetoclax (dose standard therapy: escalation) +azacitidine . Dose escalation cohort: venetoclax+bortezomib+de xamethasone . Safety expansion cohort: venetoclax+bortezomib+de xamethasone

Primary . Safety/MTD . Safety/MTD . Overall response rate . Safety endpoint

Status . FPI Q4 2012 . FPI Q4 2012 . FPI Q4 2013 . FPI Q4 2014 . Data presented at ASCO . Data presented at ASCO . Data presented at ASH . Data to be presented at 2015 2015 2014 ASH 2015

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) 95 ASH=American Society of Hematology Factor IXa/X bispecific (RG6013, ACE910) Factor VIII mimetic for treatment of hemophilia A

Hemophilia A patients with Indication Hemophilia A inhibitors to Factor VIII

Phase I Phase I/II Phase/study Non-Interventional study Study in Japan Study in Japan

# of patients N=82 N=16 N=70

Design . Enrolled 64 HVs and 18 patients . Extension study in patients from . A single arm, multicenter, non- phase 1 interventional study evaluating bleeding incidence, health- related quality of life and safety in patients with Hemophilia A and inhibitors against Factor VIII under standard-of-care treatment

Primary . Exploratory efficacy and safety . Exploratory efficacy and safety . Number of bleeds over time, endpoint sites of bleed, type of bleed

Status . Recruitment completed Q2 2014 . Recruitment completed Q4 2014 . FPI Q2 2015 . Data presented at ASH 2014 . Data presented at ISTH 2015

In collaboration with Chugai 96 ASH=American Society of Hematology, ISTH=International Society on Thrombosis and Haemostasis Bitopertin (GlyT-1, RG1678) A small molecule first-in-class glycine reuptake inhibitor (GRI)

Indication Obsessive-compulsive disorder

Phase II Phase/study SKYLYTE

# of patients N=99

Design . 16-week treatment period . Background therapy of selective serotonin reuptake inhibitors (SSRI) •ARM A: bitopertin daily (30 mg) •ARM B: bitopertin daily (10 mg) •ARM C: placebo

Primary . Change in total score on Yale-Brown Obsessive Compulsive Scale endpoint

Status . FPI Q4 2012 . Primary endpoint not met . Program discontinued Q3 2015

97 Crenezumab (RG7412) A humanized monoclonal antibody designed to target all forms of amyloid-beta

Indication Alzheimer’s Disease

Phase II Phase II Phase/study ABBY BLAZE Cognition study Biomarker study

# of patients N=446 N=91

Design . ARM A: crenezumab SC . ARM A: crenezumab SC . ARM B: crenezumab IV . ARM B: crenezumab IV . ARM C: placebo . ARM C: placebo

Primary . Change in cognition (ADAS-cog) and Clinical . Change in brain amyloid load from baseline to endpoint Dementia Rating, Sum of Boxes (CDR-SOB) score week 69 from baseline to week 73

Status . Enrollment completed Q3 2012 . Enrollment completed Q3 2012 . Positive trend in cognition was observed in ARM B . Cognition data presented at AAIC 2014 for people with milder disease . Exploratory amyloid PET analysis suggests reduced . Data presented at AAIC 2014 amyloid accumulation in ARM B . Biomarker data presented at CTAD 2014

In-licensed from AC Immune 98 AAIC=Alzheimer’s Association International Conference; CTAD=Clinical Trials on Alzheimer’s Disease Crenezumab (RG7412) A humanized monoclonal antibody designed to target all forms of amyloid-beta

Alzheimer’s Prevention Initiative (API) Indication Mild to Moderate Alzheimer's disease Colombia Phase II Phase/study Phase I Cognition study # of patients N=72 N=300

Design . ARM A/B: crenezumab dose I & placebo . ARM A: 100 carriers receive crenezumab SC . ARM C/D: crenezumab dose II & placebo . ARM B: 100 carriers receive placebo . ARM E/F: crenezumab dose III & placebo . ARM C: 100 non-carriers receive placebo

Primary . Safety (incidence and nature of MRI safety . Change on Alzheimer's Prevention Initiative (API) endpoint findings) and PK Composite Cognitive Test total score

Status . FPI Q1 2015 . FPI Q4 2013

In-licensed from AC Immune 99 Gantenerumab (RG1450) Fully human monoclonal antibody designed to bind to aggregated forms of amyloid-beta

Indication Prodromal Alzheimer’s Disease Mild Alzheimer’s Disease

Phase II/III Phase III Phase/study SCarlet RoAD Marguerite RoAD

# of patients N=799 N=1,000

Design . 104-week subcutaneous treatment period . 104-week subcutaneous treatment period . ARM A: gantenerumab (225 mg) . ARM A: gantenerumab . ARM B: gantenerumab (105 mg) . ARM B: placebo . ARM C: placebo

Primary . Change in CDR-SOB at 2 years . Change in ADAS-Cog and CDR-SB at 2 endpoint . Sub-study: change in brain amyloid by PET years (co-primary) at 2 years

Status . Phase I PET data: Archives of Neurology . FPI Q1 2014 2012 Feb;69(2):198-207 . Enrollment stopped . Enrollment completed Q4 2013 . Study to be converted into open label . Dosing stopped due to futility Q4 2014 extension to explore higher doses of . Data presented at AAIC 2015 gantenerumab . Study to be converted into open label extension to explore higher doses of gantenerumab

In collaboration with Morphosys CDR-SOB=Clinical Dementia Rating scale Sum of Boxes 100 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin

Indication Ulcerative colitis patients who are TNF naïve

Phase III Phase III Phase III Phase/study HIBISCUS I HIBISCUS II GARDENIA Induction study Induction study Sustained remission study

# of patients N=350 N=350 N=720

Design . ARM A: etrolizumab 105mg SC q4w . ARM A: etrolizumab 105mg SC q4w Time on treatment 54 weeks + adalimumab placebo SC + adalimumab placebo SC . ARM A: etrolizumab 105mg SC q4w . ARM B: etrolizumab placebo SC + . ARM B: etrolizumab placebo SC + + placebo IV adalimumab SC adalimumab SC . ARM B: placebo SC q4w + . ARM C: etrolizumab placebo SC + . ARM C: etrolizumab placebo SC + inflixumab IV adalimumab placebo SC adalimumab placebo SC

Primary . Induction of remission compared with . Induction of remission compared with . Proportion of patients in sustained endpoint placebo as determined by the Mayo placebo as determined by the Mayo clinical remission as determined by Clinic Score (MCS) at week 10 Clinic Score (MCS) at week 10 Mayo Clinic Score (MCS) at weeks 10, 30 and 54

Status . FPI Q4 2014 . FPI Q4 2014 . FPI Q4 2014

101 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin (continued)

UC patient who are TNF naïve and refractory or UC patient who are refractory or intolerant of TNF Indication intolerant to immunosuppressant and/or corticosteroid inhibitors treatment Phase III Phase III Phase/study LAUREL HICKORY Maintenance study Induction and maintenance study

# of patients N=350 N=800

Design Induction phase: Cohort 1 (open-label): . ARM A: open label etrolizumab 105mg SC q4w . ARM A: etrolizumab induction + placebo maintenance . ARM B: etrolizumab induction + maintenance Maintenance study: . ARM B: etrolizumab 105mg SC q4w Cohort 2 (blinded): . ARM C: placebo . ARM A: etrolizumab induction + maintenance . ARM B: placebo induction + maintenance

Primary . Maintenance of remission (at week 62) among randomized . Clinical Remission (Mayo Clinic Score, MCS) at Week 14 endpoint patients in remission at Week 10 as determined by the Mayo . Remission maintenance (by MCS, at Week 66) among Clinic Score (MCS) patients with remission at Week 14

Status . FPI Q3 2014 . FPI Q2 2014

UC=ulcerative colitis 102 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin (continued)

Indication Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis

Phase II Phase III Phase/study SPRUCE COTTONWOOD Open label extension study Open label extension study

# of patients N=116 N=2,600

Design . Patients who were enrolled in EUCALYPTUS . Patients who were previously enrolled in study and meet enrollment criteria will receive etrolizumab phase III studies and meet etrolizumab 105 sc q4w enrollment criteria will receive etrolizumab 105 sc q4w

Primary . Safety . Long-term efficacy as determined by partial endpoint Mayo Clinic Score (pMCS) . Incidence of adverse events

Status . Recruitment completed . FPI Q3 2014

103 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin (continued)

Moderately to severely active Crohn's Moderately to severely active Crohn's Indication disease disease

Phase III Phase III Phase/study BERGAMOT JUNIPER

# of patients N=1,250 N=1,250

Design . ARM A: etrolizumab SC 210 mg (induction . Etrolizumab SC 105mg q4w only) . ARM B: etrolizumab SC 105 mg and maintainance . ARM C: placebo

Primary . Induction and maintenance of clinical remission . Safety endpoint

Status . FPI Q1 2015 . FPI Q2 2015

104 HCV: Danoprevir (RG7227) IFN-based triple regimen for treatment-naïve patients of Asian origin conducted in China

Treatment-naïve patients of Asian origin with chronic hepatitis C Indication genotype 1 with or without cirrhosis

Phase II Phase/study DAPSANG

# of patients N=61

Design . Without cirrhosis: . ARM A: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 12 weeks

. With compensated cirrhosis: . ARM B: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks

Primary . Safety endpoint

Status . Recruitment completed Q4 2013 . Results presented at APASL 2015 . All subsequent studies will be conducted by Ascletis

In collaboration with Ascletis 105 APASL=Asian Pacific Association for the Study of the Liver Lampalizumab (RG7417) Antibody fragment to selectively block activation of alternative complement pathway

Indication Geographic atrophy (GA) secondary to age-related macular degeneration

Phase III Phase III Phase/study Phase II CHROMA SPECTRI

# of patients N=936 N=936 N=100

Design . ARM A: lampalizumab 10mg q4w . ARM A: lampalizumab 10mg q4w . ARM A: lampalizumab 10mg q2w . ARM B: lampalizumab 10mg q6w . ARM B: lampalizumab 10mg q6w . ARM B: lampalizumab 10mg q4w . ARM C: placebo . ARM C: placebo . ARM C: placebo

. Primary: change in GA area . Primary: change in GA area . Change in GA area Primary . Secondary: change in BCVA and in . Secondary: change in BCVA and in endpoint additional measures of visual additional measures of visual function function

Status . FPI Q3 2014 . FPI Q3 2014 . FPI Q4 2014 . Design presented at EURETINA . Design presented at EURETINA 2014 2014 . Fast track designation received Q4 . Fast track designation received Q4 2014 2014

EURETINA=European Society of Retina Specialists 106 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Severe uncontrolled adult asthma

Adult patients whose Indication asthma is uncontrolled with inhaled corticosteroids and a second controller medication

Phase III Phase III Phase/study LAVOLTA I LAVOLTA II

# of N=1,050 N=1,050 patients

Design . Subcutaneous lebrikizumab q4w on top of SOC for . Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up 52 weeks safety follow-up . ARM A: lebrikizumab high dose . ARM A: lebrikizumab high dose . ARM B: lebrikizumab low dose . ARM B: lebrikizumab low dose . ARM C: placebo . ARM C: placebo . Patients will be tested for periostin level . Patients will be tested for periostin level

Primary . Rate of asthma exacerbations during the 52-week . Rate of asthma exacerbations during the 52-week endpoint placebo-controlled period placebo-controlled period

Status . Enrollment completed Q4 2014 . Enrollment completed Q4 2014 . Expect data in 2016 . Expect data in 2016

107 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 (continued)

Adolescent patients whose asthma is uncontrolled with inhaled Indication Idiopathic pulmonary fibrosis corticosteroids and a second controller medication Phase III Phase II Phase/study ACOUSTICS RIFF

# of patients N=375 N=300

Design . Subcutaneous lebrikizumab q4w on top of SOC . ARM A: lebrikizumab SC q4w for 52 weeks with 52 week double-blind active . ARM B: placebo treatment extension . ARM C: lebrikizumab SC q4w + Esbriet . ARM A: lebrikizumab high dose, week 1-104 or . ARM D: Esbriet week 52-104 . ARM B: lebrikizumab low dose, week 1-104 or week 52-104 . ARM C: placebo, week 1-52

Primary . Rate of asthma exacerbations during the 52- . Change in FVC at week 52 endpoint week placebo-controlled period

Status . FPI Q3 2013 . FPI Q4 2013 (arms A&B) . FPI in Esbriet arms in Q3 2015

SOC=Standard of Care; OCS=Oral Corticosteroids 108 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 (continued)

Adult asthma Indication Adult asthma mild-to-moderate Adult asthma patients Phase II Phase II Phase III CLAVIER Phase/study VOCALS STRETTO Mechanistic biomarker study

# of patients N=225 N=300 N=120

Design . ARM A: lebrikizumab high . ARM A: lebrikizumab SC . ARM A: lebrikizumab SC dose SC q4w q4w q4w . ARM B: lebrikizumab low . ARM B: placebo . ARM B: placebo dose SC q4w . ARM C: Montelukast . ARM C: placebo

. Relative change in OCS . Absolute change in FEV1 at . Relative change in airway Primary dose at week 44 week 12 inflammation endpoint (eosinophils/mm2) at week 12

Status . FPI Q1 2014 . Recruitment completed Q3 . FPI Q4 2014 2015 . Data expected in 2016

109 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 (continued)

Moderate to very severe Indication Moderate-to-severe atopic dermatitis COPD Phase II Phase II Phase II Phase/study ARBAN TREBLE VALETA Safety Study

# of patients N=200 N=50 N=300

Design Patients on topical . ARM A: lebrikizumab Patients on background SOC corticosteroids . ARM B: topical during study . ARM A: lebrikizumab dose 1 corticosteroids . ARM A: lebrikizumab SC q4w . ARM B: lebrikizumab dose 2 . ARM B: placebo . ARM C: lebrikizumab dose 3 . ARM D: placebo

. Percentage of patients . Safety comparison of . Week 24 change from Primary achieving a 50% reduction in lebrikizumab vs. TCS baseline in pre-bronchodilator endpoint Eczema Area and Severity forced expiratory volume Index (EASI) score (EASI-50) (FEV-1) from baseline to week 12

Status . FPI Q2 2015 . FPI Q3 2015 . FPI Q3 2015

TCS=topical corticosteroids 110 Ocrelizumab (RG1594) A humanized monoclonal antibody designed to selectively target CD20-positive B cells

Primary progressive Indication Relapsing multiple sclerosis (RMS) multiple sclerosis (PPMS)

Phase III Phase III Phase III Phase/study OPERA I OPERA II ORATORIO

# of patients N=800 N=800 N=630

Design . 96-week treatment period: . 96-week treatment period: . 120-week treatment period: . ARM A: Ocrelizumab 2x 300 mg . ARM A: Ocrelizumab 2x 300 mg . ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 iv followed by 600 mg iv every 24 iv every 24 weeks weeks weeks . ARM B: Placebo . ARM B: Interferon -1a . ARM B: Interferon -1a

Primary . Annualized relapse rate at 96 . Annualized relapse rate at 96 . Sustained disability progression endpoint weeks versus Rebif weeks versus Rebif versus placebo by Expanded Disability Status Scale (EDSS)

Status . Primary endpoint met Q2 2015 . Primary endpoint met Q2 2015 . Primary endpoint met Q3 2015 . Expect global filing in 2016 . Expect global filing in 2016 . Expect global filing in 2016

111 Olesoxime (RG6083) Novel small molecule neuroprotectant that preserves mitochondrial function

Indication Spinal muscular atrophy

Phase II Phase/study Registrational study

# of patients N=165

Design . ARM A: olesoxime . ARM B: placebo

Primary . Motor function measure endpoint

Status . Study completed Q4 2013 . Presented at AAN 2014

Collaborator Trophos acquisition

112 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 113 Oncology development programmes Small molecules

Idasanutlin MDM2 antagonist IV LSD1 inhibitor Raf/MEK inhibitor Molecule (MDM2 antagonist, prodrug (RG6016) (RG7304, CKI27) RG7388) (RG7775)

Advanced cancers Indication Acute myeloid leukemia Acute Leukemia Solid tumors including AML

Phase Phase I Phase I Phase I Phase I

# of patients N=100 N=90 N=30 N=52

Design . Multiple ascending dose- Dose-escalation study . Multiple ascending . Dose-escalation to MTD escalation study . ARM A: patients with dose-escalation study advanced solid tumors . ARM B: patients with r/r AML

Primary . MTD . MTD . MTD . MTD and tumor endpoint assessment

Status . FPI Q1 2013 . FPI Q2 2014 . FPI Q1 2014 . Initiated Q4 2008 . Preliminary results . Extension in MLL-AML . Enrollment stopped in presented at ASH 2014 initiated Q3 2015 Q4 2010 . Enrollment completed Q3 2015

Collaborator Oryzon Genomics, S.A. Chugai

ASH=American Society of Hematology 114 Oncology development programmes Monoclonal antibodies

Glypican-3 MAb Molecule (GC33, RG7686) Metastatic liver cancer 2L metastatic liver cancer Indication (hepatocellular carcinoma) (hepatocellular carcinoma) Phase Phase Ib Phase II

# of patients N= 40-50 N=185

Design . Study US monotherapy . Adaptive design study . Study Japan monotherapy Double blind randomized 2:1 RG7686: placebo . Dose escalation study in combo with SOC . Patients are stratified according to the level of GPC-3 expression in tumor

Primary . Safety and tolerability . Progression-free survival endpoint

Status . Recruitment completed Q4 2013 . Recruitment completed Q1 2013 . Data presented at ASCO 2014 . Data presented at ASCO 2014 . Further steps under evaluation . Further steps under evaluation

Collaborator Chugai

SOC=standard of care; ASCO=American Society of Clinical Oncology 115 Oncology development programmes Monoclonal antibodies (continued)

Lumretuzumab Vanucizumab Molecule (GE-huMAb HER3 MAb, RG7116) (Ang2-VEGF MAb, RG7221)

HER2-low and HER3-positive Indication Solid tumors Solid tumors Metastatic colorectal cancer metastatic breast cancer

Phase II Phase Phase I Phase I Phase I McCAVE

# of patients N=105 N=40 N≈80 N=140

Design . Multiple ascending dose study . Multiple ascending dose of . Multiple ascending dose study . ARM A: Induction: with extension cohorts and RG7116 in combination with with extension cohorts in solid Avastin+mFOLFOX-6; followed imaging sub-study Perjeta and paclitaxel tumors to assess the PD effects by maintenance: Avastin+5- . Combination arms with HER1- and platinum-resistant ovarian FU/LV targeted therapies (erlotinib, cancer . ARM B: Induction: cetuximab) RG7221+mFOLFOX-6; followed by maintenance: RG7221+5- FU/LV

Primary endpoint . Safety, PK . Safety, PK . Safety, PK . Progression-free survival

Status . FPI Q4 2011 . FPI Q3 2013 . FPI Q4 2012 . Recruitment completed Q1 . Initial data presented at ASCO . Dose escalation data presented 2015 2013 at ASCO 2014 . Data expected in 2016 . Ovarian cancer cohort data presented at ASCO 2015 . Biomarker/imaging data presented at ECC 2015

ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress 116 Oncology development programmes Monoclonal antibodies (continued)

Emactuzumab CEA-IL2v Molecule (CSF-1R huMAb, RG7155) (RG7813)

Indication Solid tumors and PVNS Solid tumors Solid tumors Solid tumors

Phase Phase I/II Phase I Phase I Phase Ib

# of patients N≈140 N=110 N~110 N=75

Design . Multiple ascending dose RG7155 in combination with . Single and multiple dose . Part 1: dose escalation of study +/- paclitaxel with atezolizumab (PD-L1 MAb) escalation study with RG7813 in combination with extension cohorts . Part 1: dose escalation extension cohorts atezolizumab (PD-L1 MAb) . Part 2: expansion . Part 2: dose expansion RG7813 in combination with atezolizumab (PD-L1 MAb)

Primary . Safety, PK, PD & preliminary . Safety . Safety, PK, PD . Safety, Efficacy, PK, PD endpoint clinical activity

Status . FPI Q4 2011 . FPI Q1 2015 . FPI Q4 2013 . FPI in Q2 2015 . Biomarker data presented at . Imaging data presented at AACR 2013 and AACR 2014 ASCO 2015 . Data presented at ASCO . Biomarker/imaging data 2014 presented at ECC 2015 . Updated data presented at ASCO 2015

AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology; 117 ECC=European Cancer Congress Oncology development programmes Monoclonal antibodies (continued)

CEA CD3 T-cell bispecific (TCB) CD40 iMAb (RG7876) in combination FAP-DR5 Molecule (RG7802) with atezolizumab (PD-L1 MAb) (RG7386)

Indication CEA-positive solid tumors Solid tumors Solid tumors

Phase Phase Ia Phase I Phase I

# of patients N=90 N=160 N=120

Design . Multiple ascending dose study with . Part I: sequential administration of . Part I: Dose escalation extension cohorts and imaging sub- RG7876 and atezolizumab (PD- . Part II: Tumor biopsy and imaging study L1 MAb) evaluation for assessment of treatment- . Part II: concomitant administration of induced pharmacodynamic (PD) effects RG7876 and atezolizumab (PD- . Part III: Evaluation of anti-tumor activity L1 MAb) of single agent RO6874813 patients with . Part III: study drugs schedule in histologically confirmed recurrent or specific indication per Part II metastatic, non-resectable FAP+ sarcomas with two or fewer prior regimens for advanced disease

Primary . Safety, PK, PD, imaging, BM . Safety . Parts I & II – Safety and tolerability endpoint . Part III – antitumor activity

Status . FPI Q4 2014 . FPI Q4 2014 . FPI October 2015

118 Neuroscience development programmes

Basmisanil Molecule (GABRA5 NAM, RG1662)

Down Syndrome Children 6 to 11 Years of Indication Down Syndrome Age

Phase IIB Phase Phase II CLEMATIS

# of patients N=180 N=36

Design . For 26 weeks patients will receive: . For 26 weeks patients will receive 1 of 3 . ARM A: RG1662 120mg twice daily dosages of RG1662 PO BID, Including 40 mg, . ARM B: RG1662 120mg twice daily 60 mg, or 120 mg . ARM C: Placebo

Primary . Cognition and adaptive behavior . PK, PD, efficacy, safety, and tolerability endpoint

Status . FPI Q2 2014 . Expect FPI Q3 2015

NAM=Negative allosteric modulator 119 Neuroscience development programmes (continued)

V1 receptor antagonist SMN2 splicing modifier Basimglurant Molecule (RG7314) (RG7800) (mGlu5 NAM, RG7090)

Adjunctive Treatment of Major Indication Autism Spinal muscular atrophy Depressive Disorder

Phase II Phase Ib Phase II Phase VANILLA MOONFISH Marigold

# of patients N=225 N=48 N=300

Design . Multi-center, randomized, double- . Randomized, double-blind, 12-week, . ARM A: basimglurant 0.5 mg blind, placebo-controlled proof-of- placebo-controlled multiple dose . ARM B: basimglurant 1.5 mg concept study in individuals with study in adult and pediatric patients . ARM C: matching placebo Autism Spectrum Disorder (ASD)

Primary . Safety and efficacy . Safety and tolerability . Efficacy - Montgomery Asberg endpoint Depression Rating Scale

Status . FPI Q3 2013 . Study on hold . Study completed . First cohort completed . Data presented at ECNP, ACNP 2014 & ASCP 2015 . Program to be licensed out

Collaborator PTC Therapeutics/ SMA Foundation

ECNP=European College of Neuropsychopharmacology; ACNP=American College of Neuropsychopharmacology 120 ASCP=American Society of Clinical Phsycopharmacology Neuroscience development programmes (continued)

Anti-aSynuclein Molecule (RG7935, PRX002)

Indication Parkinson’s disease

Phase Phase I Phase I

# of patients N=40 N=up to 60

Design . Double-blind, placebo-controlled, . Double-blind, placebo-controlled, single, ascending dose study of multiple ascending dose study of RG7935 in healthy subjects RG7935 in patients with Parkinson’s disease

Primary . Safety, tolerability and PK . Safety and tolerability endpoint

Status . Study completed Q1 2015 . FPI Q3 2014 . Data presented at MDS 2015

Collaborator Prothena

121 MDS=Movement Disorder Society Infectious diseases development programmes

DBO Beta lactamase HBV therapeutic vaccine NME TLR7 agonist Molecule inhibitor (RG7944, INO-1800 and INO- (RG7689) (RG7795) (RG6080) 9112))

Indication Infectious diseases Infectious diseases Chronic hepatitis B Chronic hepatitis B

Phase Phase I Phase I Phase II Phase I

# of patients N=77 N=40 N=40 N=126

Design . Double-blind, randomized, . Randomized, double-blind, . Various doses of RG7795 . INO-1800, alone or in placebo-controlled, single- placebo-controlled, single- vs. placebo combination with INO- ascending dose (SAD) and ascending dose study in 9112 multiple-ascending dose healthy volunteers (MAD) study in healthy volunteers

Primary . Safety, PK/PD . Safety, PK . Safety, efficacy . Safety, tolerability and endpoint immunogenicity

Status . FPI Q4 2014 . Study completed . FPI Q2 2015 . FPI Q2 2015

Collaborator Meiji and Fedora Inovio

122 Ophthalmology and immunology development programmes

VEGF/Ang2 MAb Cathepsin S inhibitor Molecule (RG7716) (RG7625)

Wet age-related macular Indication Autoimmune diseases Autoimmune diseases degeneration

Phase/study Phase II Phase I Phase I

# of patients N=271 N=16 N=36

Design . Arm A: SoC (Lucentis, q4w . Single ascending dose (SAD) of . MAD study of RG7625, healthy . Arm B: 1.5 mg VA2, q4w RG7625 in healthy volunteers volunteers . Arm C: 6mg VA2, q4w / q8w . Arm E: Soc q4w x 3 doses, switch group to 6 mg VA2 q4w

Primary . Visual acuity (change in . Safety, PK, PD . Safety, PK, PD endpoint BCVA) after 32 weeks

Status . FPI Q3 2015 . SAD completed Q2 2015 . FPI Q3 2015

123 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 124 Oncology development programmes Monoclonal antibodies

Duligotuzumab OX40 MAb CD20/CD3 biMAb Molecule (HER3/EGFR DAF MAb, RG7597) (RG7888, MOXR0916) (RG7828)

Locally advanced or Indication metastatic tumors with Solid tumors Solid tumors Hematologic tumors mutant KRAS

Phase Phase I Phase I Phase I Phase I

# of patients N=50 N=400 N=360 N=170

Design . Dose finding of duligotuzumab . RG7888 dose escalation . RG7888 plus atezolizumab . Dose escalation and plus cobimetinib* (MEK and expansion study (PD-L1 MAb) dose expansion inhibitor) escalation and expansion

Primary . Safety . Safety . Safety . Safety, PK/PD endpoint

Status . FPI Q4 2013 . FPI Q3 2014 . FPI Q2 2015 . FPI Q3 2015

*Cobimetinib in collaboration with Exelixis 125 Oncology development programmes Antibody-drug conjugates

STEAP1 ADC NME ADC Ly6E ADC Molecule (RG7450) (RG7882) (RG7841)

Pt-resistant ovarian cancer or HER2-neg. breast cancer and Indication Prostate cancer unresectable pancreatic cancer NSCLC Phase Phase I Phase I Phase I

# of patients N=84 N=95 N=115

Design . Dose escalation and expansion study . Dose escalation and expansion . Dose escalation study study

Primary endpoint . Safety . Safety/PK . Safety

Status . Dose escalation study: enrollment . FPI Q2 2014 . FPI Q2 2014 completed Q1 2014 . Expansion study: FPI Q2 2015 . Expansion study: enrollment completed Q2 2015 . Data presented at ASCO 2013- 2015 & AACR 2014-2015 Collaborator Seattle Genetics Seattle Genetics and Agensys

ASCO=American Society of Clinical Oncology; AACR=American Association for Cancer Research 126 Oncology development programmes Antibody-drug conjugates (continued)

Lifastuzumab vedotin NME ADC Molecule (NaPi2b ADC, RG7599) (RG7986)

Platinum-sensitive Relapsed or Refractory NSCLC and ovarian Platinum-resistant Indication ovarian cancer and B-cell Non-Hodgkins cancer ovarian cancer NSCLC Lymphoma Phase II Phase Phase I Phase Ib Phase I HERAEA

# of patients N=96 N=54 N=92 N=80

Design . Dose escalation study . Dose escalation of . ARM A: RG7599 . Dose escalation and RG7599 in combination . ARM B: Pegylated expansion with carboplatin, with or liposomal doxorubicin without Avastin

Primary . Safety . Safety, PK . Progression-free survival . Safety, PK endpoint

Status . FPI Q2 2011 . FPI Q4 2013 . Recruitment completed . FPI Q3 2015 . Data presented at ASCO Q1 2015 2014 . Data expected in 2016 Collaborator Seattle Genetics

ASCO=American Society of Clinical Oncology 127 Oncology development programmes Small molecules

Indoleamine 2, 3-dioxygenase (IDO) Inhibitor Molecule (RG6078, GDC-0919, NLG919)

Indication Solid tumors Solid tumors

Phase Phase I Phase I

# of patients N=36 N=224

Design . Dose escalation study . Dose escalation and expansion study of IDO and atezolizumab (PD-L1 MAb) combination

Primary . Safety . Safety, tolerability, and PK endpoint

Status . FPI Q1 2014 . FPI Q3 2015

Collaborator NewLink Genetics

128 Oncology development programmes Small molecules (continued)

ChK1 inhibitor ERK inhibitor Molecule (RG7741,GDC-0575) (RG7842, GDC-0994)

Indication Solid tumors Solid tumors Solid tumors

Phase Phase I Phase I Phase I

# of patients N=91 N=78 N=142

Design . Stage 1: Dose escalation . Stage 1: Dose escalation . Dose escalation study of . Stage 2: Cohort expansion . Stage 2: Cohort expansion RG7842 and cobimetinib (MEK inhibitor)* combination

Primary . Safety/PK . Safety, MTD, PK . Safety and tolerability endpoint

Status . FPI Q2 2012 . FPI Q2 2013 . FPI Q2 2015

Collaborator Array BioPharma

*Cobimetinib in collaboration with Exelixis 129 Oncology development programmes Small molecules (continued)

Selective estrogen receptor degrader Selective estrogen receptor degrader Molecule (SERD) (SERD(2)) (RG6046, GDC-0810/ARN-810) (RG6047, GDC-0927/SRN-927)

Metastatic ER+ HER2-neg. breast Metastatic ER+ HER2-neg. breast Indication cancer cancer

Phase Phase I/IIa Phase I

# of patients N=141 N=90

Design . Phase I: dose escalation . Dose escalation study . Phase IIa: dose expansion

Primary . Safety, PK, MTD . Safety endpoint

Status . FPI Q4 2014 . FPI Q1 2015 . Initial data presented at SABCS 2014 and AACR 2015

Collaborator Seragon acquisition

SABCS=San Antonio Breast Cancer Symposium; AACR=American Association for Cancer Research 130 Oncology development programmes Small molecules (continued)

Ipatasertib Molecule (AKT inhibitor, RG7440, GDC-0068) 1L metastatic gastric or 2L castration-resistant Indication gastroesophageal junction 1L triple-negative breast cancer prostate cancer adenocarcinoma Phase II Phase II Phase II Phase A.MARTIN JAGUAR LOTUS # of patients N=262 N=153 N=120

Design . ARM A: ipatasertib (400mg) + . ARM A: ipatasertib + mFOLFOX6 . ARM A: ipatasertib + paclitaxel abiraterone . ARM B: placebo + mFOLFOX6 . ARM B: placebo + paclitaxel . ARM B: ipatasertib (200mg) + abiraterone . ARM C: placebo + abiraterone

Primary . Progression-free survival . Progression-free survival . Progression-free survival endpoint

Status . Enrollment completed Q4 2014 . Enrollment completed Q4 2014 . FPI Q3 2014 . Data expected in 2015 . Data expected in 2015

Collaborator Array BioPharma

mFOLFOX6=modified FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) 131 Oncology development programmes Small molecules (continued)

Ipatasertib Molecule (AKT inhibitor, RG7440, GDC-0068)

Indication Solid tumors Neoadjuvant TNBC

Phase II Phase Phase Ib FAIRLANE # of patients N=120 N=150

Design . Dose escalation with: . ARM A: ipatasertib + paclitaxel . ARM A: docetaxel . ARM B: placebo + paclitaxel . ARM B: fuoropyrimidine plus oxaliplatin . ARM C: paclitaxel . ARM D: enzalutamide

Primary . Safety . Pathologic complete response (pCR) endpoint

Status . FPI Q3 2011 . FPI Q1 2015 . Data presented at ESMO and SABCS 2014

Collaborator Array BioPharma

ESMO=European Society for Medical Oncology; SABCS=San Antonio Breast Cancer Symposium 132 Immunology, infectious disease and neuroscience development programmes

NME NME Anti-Flu A Anti-Flu B Molecule (RG7880) (RG6069, GDC-3280) (RG7745) (RG6024) Inflammatory Indication Fibrosis Influenza A Influenza B diseases

Phase Phase I Phase I Phase IIb Phase I

# of patients N=74 N=88 N~300 N=26

Design • Healthy volunteer . Randomized, double- Hospitalized patients . Randomized, double blind, study blind, placebo-controlled, requiring oxygen with placebo controlled, ascending, single- and severe influenza A healthy volunteer, single multiple-oral dose study . ARM A: RG7745 + Tamiflu ascending dose study . ARM B: placebo + Tamiflu

Primary • Safety and . Safety, tolerability, and PK . Safety and efficacy (time . Safety, tolerability, and PK endpoint tolerability to normalization of respiratory function)

Status • FPI Q4 2014 . FPI Q2 2015 . FPI Q1 2015 . FPI Q3 2015

133 Immunology, infectious disease and neuroscience development programmes (continued)

Nav1.7 Nav1.7 (2) Molecule (RG7893, GDC-0276) (RG6029, GDC-0310)

Indication Pain Pain

Phase Phase I Phase I

# of patients N=254 N=228

Design . Phase 1, randomized, placebo- . Randomized, placebo-controlled, controlled, double blinded study in double blinded study to determine healthy volunteers safety, tolerability and pharmacokinetics in healthy volunteers

Primary endpoint . Safety, tolerability, and . Safety, tolerability, and pharmacokinetics of single and pharmacokinetics of single and multiple doses multiple doses

Status . FPI Q3 2014 . FPI Q3 2015

Collaborator Xenon Pharmaceuticals Inc.

134 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 135 YTD Sept 2015: Geographical sales split by divisions and Group* CHFm 2015 2014 % change CER Pharmaceuticals Division 27,690 26,965 +6 United States 13,047 11,528 +7 Europe 6,476 7,070 +3 Japan 2,341 2,406 +8 International 5,826 5,961 +6 Diagnostics Division 7,835 7,792 +6 United States 1,857 1,736 +1 Europe 2,780 3,058 +2 Japan 286 333 -5 International 2,912 2,665 +14 Group 35,525 34,757 +6 United States 14,904 13,264 +6 Europe 9,256 10,128 +3 Japan 2,627 2,739 +6 International 8,738 8,626 +8 136 * Geographical sales split shown here does not represent operational organisation; CER=constant exchange rates Pharma Division sales YTD Sept 2015 (vs. 2014) Top 20 products

Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER MabThera/Rituxan 5,268 5 2,822 7 1,350 0 166 11 930 7 Avastin 4,968 9 2,286 8 1,348 4 538 15 796 18 Herceptin 4,879 10 1,785 16 1,500 0 190 5 1,404 15 Lucentis 1,142 -15 1,142 -15 ------Actemra/RoActemra 1,042 22 397 28 344 21 160 14 141 23 Perjeta 1,035 66 587 46 302 117 61 17 85 145 Xolair 932 25 932 25 ------Tarceva 894 -7 478 -7 168 -17 68 2 180 2 Activase/TNKase 676 15 644 16 - - - - 32 -8 CellCept 582 -4 147 -10 131 -10 40 5 264 1 Kadcyla 558 57 229 1 235 137 42 122 52 134 Tamiflu 535 16 412 54 13 -81 53 -6 57 -3 Pulmozyme 472 11 326 9 86 4 - - 60 32 Pegasys 405 -48 42 -76 79 -54 13 -70 271 -30 Esbriet 386 - 262 - 106 - - - 18 - Xeloda 384 -36 43 -76 32 -52 64 6 245 -19 Mircera 369 29 - - 65 -3 135 4 169 102 NeoRec./Epogin 272 -12 - - 115 -10 35 -11 122 -15 Valcyte/Cymevene 270 -47 56 -82 116 -4 - - 98 -5 Rocephin 206 4 - - 28 0 22 -3 156 6

CER=constant exchange rates 137 Pharma Division sales YTD Sept 2015 (vs. 2014) Recently launched products

Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Zelboraf 158 -25 32 -43 92 -28 3 - 31 13 Erivedge 118 30 83 38 26 1 - - 9 119 Gazyva 91 182 55 71 15 * - - 21 *

CER=constant exchange rates 138 * over +500%

Pharma Division CER sales growth1 in % Global top 20 products Q3/14 Q4/14 Q1/15 Q2/15 Q3/15 MabThera/Rituxan 1 -1 5 6 4 Avastin 6 7 6 13 8 Herceptin 9 7 12 10 7 Lucentis 2 -5 -9 -16 -18 Actemra/RoActemra 28 20 27 23 18 Perjeta 227 103 82 64 57 Xolair 33 29 28 27 21 Tarceva 0 -2 -3 -10 -7 Activase/TNKase 19 5 15 16 14 CellCept 0 -4 -7 -1 -4 Kadcyla 103 110 80 54 44 Tamiflu 121 129 6 61 46 Pulmozyme 13 4 4 15 14 Pegasys -22 -29 -39 -58 -45 Esbriet - - - - - Xeloda -61 -56 -53 -29 -11 Mircera -1 0 17 17 55 NeoRec./Epogin -12 -1 -10 -19 -8 Valcyte/Cymevene 19 -9 -41 -47 -52 Rocephin 18 14 18 0 -8 CER=constant exchange rates 139 1 Q3-Q4/14 vs. Q3-Q4/13; Q1-Q3/15 vs. Q1-Q3/14 Pharma Division CER sales growth1 in % Top 20 products by region US Europe Japan International Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 MabThera/Rituxan 5 10 7 4 7 1 -1 1 -4 1 28 7 -17 2 13 5 Avastin 7 6 11 6 3 3 4 5 5 4 29 13 16 11 27 16 Herceptin 17 18 18 12 2 0 -1 0 -7 -7 22 3 6 23 14 9 Lucentis -5 -9 -16 -18 ------Actemra/RoActemra 31 35 30 21 22 24 21 19 11 1 28 13 6 55 8 15 Perjeta 86 60 43 37 171 140 125 96 32 12 21 18 177 222 112 125 Xolair 29 28 27 21 ------Tarceva 9 2 -15 -7 -9 -15 -16 -20 -6 -12 8 12 -13 1 6 -1 Activase/TNKase 4 16 18 15 ------12 -2 -10 -11 CellCept -18 -17 2 -14 -11 -10 -9 -10 -13 -3 8 11 13 -2 1 5 Kadcyla -7 -1 -2 6 * 229 135 92 - - 81 39 * 333 131 74 Tamiflu 127 49 131 54 -93 -83 478 -65 190 -2 -97 - 350 -20 18 22 Pulmozyme 9 4 15 9 -2 2 2 8 - - - - -1 9 34 49 Pegasys -49 -82 -84 -45 -46 -55 -58 -45 -1 -50 -73 -82 -17 -8 -42 -40 Esbriet ------Xeloda -92 -89 -48 3 -77 -59 -53 -41 -8 -8 22 8 -10 -17 -27 -11 Mircera - - - - -8 -3 -3 -1 -11 -14 23 6 30 99 24 206 NeoRec./Epogin - - - - -10 -10 -11 -9 -39 -24 0 -7 28 -6 -29 -8 Valcyte/Cymevene -13 -76 -83 -86 -9 -2 -8 -1 - - - - -1 4 -1 -17 Rocephin - - - - 7 14 -8 -15 -15 -9 1 -2 30 25 2 -7 CER=constant exchange rates (avg full year 2014) * over 500% 140 1 Q4/14 vs. Q4/13; Q1-Q3/15 vs. Q1-Q3/14 CER sales growth (%) Quarterly development

2014 vs. 2013 2015 vs. 2014 Q1 Q2 Q3 Q4 Q1 Q2 Q3

Pharmaceuticals Division 4 4 4 5 4 7 6 United States 3 8 4 10 6 7 7 Europe 5 1 1 4 1 3 6 Japan 19 -4 8 5 -2 18 8 International 1 3 6 0 9 5 4

Diagnostics Division 7 5 7 7 6 7 4 Roche Group 5 4 5 6 5 7 6

CER=constant exchange rates 141 MabThera/Rituxan

Global sales CER growth Regional sales CER growth CHFbn +5% US +7% 6.0

5.0 Europe 0% 4.0 Japan +11% 3.0

2.0 International +7%

1.0

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 5.268bn • Immunology sales grew +10% (RA and GPA/MPA) • Oncology sales grew +4% (in the US mainly due to iNHL) • International: +7% growth driven by several regions, especially Latin America with Brazil and Argentina CER=constant exchange rates 142 Avastin

Global sales CER growth Regional sales CER growth CHFbn +9% US +8% 6.0

5.0 Europe +4% 4.0

3.0 Japan +15% 2.0 International +18% 1.0

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 4.968bn • US: Strong growth driven by ovarian and cervical cancer • EU: Slight growth driven by ovarian and cervical (EU approval in cervical cancer in Q1 `15) • International: Strong growth driven by all regions, especially Latin America (+29%) • Japan: Growth driven by all indications CER=constant exchange rates 143 Herceptin

Global sales CER growth Regional sales CER growth CHFbn +10% US +16% 6.0

5.0 Europe 0% 4.0

3.0 Japan +5% 2.0

1.0 International +15%

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 4.879bn • US: Strong volume growth in 1L mBC due to longer treatment times • Europe: Stable sales with switching to the subcutaneous formulation on-going • International: Strong growth across all regions, especially LATAM and China

CER=constant exchange rates 144 Lucentis

Global sales CER growth Regional sales CER growth CHFbn -15% 1.4

1.2

1.0 US -15% 0.8

0.6

0.4

0.2

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 1.142bn • US: In-class competition in wAMD and DME; First sales from DR in patients with DME after first- in-class FDA approval for DR in H1 `15

wAMD=wet age-related macular degeneration; DME=diabetic macular edema; DR=diabetic retinopathy CER=constant exchange rates 145 Actemra/RoActemra:

Global sales CER growth Regional sales CER growth CHFbn +22% US +28% 1.2

1.0 Europe +21%

0.8

0.6 Japan +14% 0.4

0.2 International +23%

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 1.042bn • US: Growth driven by continued SC uptake and increased monotherapy share • EU: Growth driven by further strengthening market leadership in monotherapy and SC adoption • International: Recent growth mainly driven by Latin America

CER=constant exchange rates 146 Perjeta

Global sales CER growth Regional sales CER growth CHFbn +66% US +46% 1.2

1.0 Europe +117%

0.8

0.6 Japan +17%

0.4 International +145%

0.2

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 1.035bn • US growth driven by 1L mBC and by neoadjuvant • EU growth driven by 1L mBC; Neoadjuvant approval in Q3 `15 achieved • International: Growth in all regions; First sales in Brazil and Argentina • Japan: Continued uptake in 1L mBC CER=constant exchange rates 147

Xolair

Global sales CER growth Regional sales CER growth CHFbn +25% 1.0

0.8 US +25% 0.6

0.4

0.2

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 0.932bn • US: Strong growth in allergic asthma and chronic idiopathic urticaria (FDA approval in Q1 `14) due to longer treatment duration

CER=constant exchange rates 148 Tarceva

Global sales CER growth Regional sales CER growth CHFbn -7% US -7% 1.2 Europe -17% 1.0

0.8 Japan +2%

0.6

0.4 International +2%

0.2

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 0.894bn • Overall: Continued decline due to in-class-competition in both 1L EGFR Mut+ NSCLC and 2/3L EGFR WT NSCLC in several regions • Avastin+Tarceva filed in the EU for 1L EGFR+ NSCLC

CER=constant exchange rates 149 Kadcyla

Global sales CER growth Regional sales CER growth CHFbn +57% US +1% 0.6

Europe +137% 0.4

0.2 Japan +122% International +134%

0.0 YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 11 12 13 14 15 YTD September 2015 sales of CHF 0.558bn • US: YTD slightly increased patient share in 2L mBC • Europe: Strong uptake in recently launched countries (e.g. Italy and France) • International: Growth driven by Brazil; Reimbursement negotiationes on-going • Japan: Reimbursement granted in H1 `15 CER=constant exchange rates 150 YTD Sept 2015: Immunology

YTD September 2015 sales of CHF 4.533bn Actemra (+22%) 2015 vs. 2014 • EU: +21% supported by growing 1L CHFbn CER growth monotherapy patient share and SC uptake +23% 5.0 • US: +28% driven by continued SC uptake +8% • International: +23% driven by all regions 4.0 +12% Xolair (+25%) • Allergic asthma and strong growth in 3.0 +19% chronic idiopathic urticaria (CIU) post FDA approval in Q1 ‘14 2.0 MabThera/Rituxan (+10%) +30% • Continues to grow in rheumatoid arthritis 1.0 and vasculitis (GPA and MPA) in the US Esbriet 0.0 YTD Sep 13 YTD Sep 14 YTD Sep 15 • Strong launch momentum in the US • Establishing market leadership in IPF US Europe International Japan

CER=constant exchange rates 151 Tamiflu quarterly sales 2011 - 2015 Retail and Governments/Corporations

500 Retail Governments & Corporations 400

300 496 277 376 200 288 302

233 214 100 177 12 70 111 26 44 32 67 17 39 7 45 46 15 31 33 0 19 3 -6 10 8 5 1 2 7 11 10 11 0 2 7

-100 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15

152 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 153 Diagnostics Division CER growth By Region and Business Area (vs. 2014)

Global North America EMEA¹ RoW % CER % CER % CER % CER CHFm growth CHFm growth CHFm growth CHFm growth

Professional Diagnostics 4'487 7 972 3 1'775 3 1'740 14 Diabetes Care 1'533 -3 262 -20 928 -1 343 9 Molecular Diagnostics 1'248 10 495 13 480 16 273 -1 Tissue Diagnostics 567 12 339 9 147 14 81 21

Diagnostics Division 7'835 6 2'068 2 3'330 4 2'437 11

CER=constant exchange rates 154 ¹ Europe, Middle East and Africa Diagnostics Division quarterly sales and CER growth1

Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER

Professional 1'512 8 1'493 8 1'648 8 1'425 6 1'547 8 1'515 7 Diagnostics

Diabetes 602 -4 581 4 671 1 507 1 550 0 476 -9 Care

Molecular 392 3 403 8 448 7 401 10 431 14 416 8 Diagnostics

Tissue 178 14 175 13 207 10 178 14 196 11 193 11 Diagnostics

Dia Division 2'684 5 2'652 7 2'974 7 2'511 6 2'724 7 2'600 4

CER=constant exchange rates 155 ¹ versus same period of prior year YTD Sept 2015: Diagnostics Division sales Growth driven by Asia Pacific and EMEA1

CHF 7'835 m CER sales growth

2'068 North America 26% Diagnostics Division 6%

EMEA¹ 4% Asia Pacific 20% 1'605 North America 2%

Asia Pacific 15%

Latin 546 Latin America 7% 13% 3'330 America 286 Japan 4% Japan -5% EMEA1 43%

CER=constant exchange rates 156 ¹ Europe, Middle East and Africa YTD Sept 2015: Diagnostics Division sales Growth driven by Professional Diagnostics

CHF 7'835 m CER sales growth

Dia 1'533 Diabetes Care 20% Division 6%

Professional Diagnostics 7% Molecular Diagnostics 16% 1'248 Diabetes Care -3%

4'487 Molecular Diagnostics 10% 567 Tissue Diagnostics 7%

Tissue Diagnostics 12% Professional Diagnostics 57%

CER=constant exchange rates 157 Professional Diagnostics

2015 vs. 2014 CHFbn CER growth

5.0 +7%

-1% 4.0 +4%

3.0 +3%

2.0

1.0 +12%

0.0 YTD Sep 13 YTD Sep 14 YTD Sep 15 Immunodiagnostics Clinical Chemistry POC products Other

CER=constant exchange rates 158 Diabetes Care

2015 vs. 2014 CHFbn CER growth

2.0 -3%

1.5 +10%

1.0 -4%

0.5

0.0 YTD Sep 13 YTD Sep 14 YTD Sep 15 Blood Glucose Monitoring Other

CER=constant exchange rates 159 Molecular Diagnostics

2015 vs. 2014 CHFbn CER growth

1.4 +10%

1.2 +38% 1.0 +12% 0.8 -5%

0.6 +4% 0.4

0.2 +13%

0.0 YTD Sep 13 YTD Sep 14 YTD Sep 15 Other HPV & Microbiology Blood Screening Biochem Reag & qPCR & NAP Systems Virology

CER=constant exchange rates 160 Tissue Diagnostics

2015 vs. 2014 CHFbn CER growth

0.6 +12% -11% 0.5 -3%

0.4 +45%

0.3

0.2 +12%

0.1

0.0 YTD Sep 13 YTD Sep 14 YTD Sep 15 Advanced Staining Companion Dia Primary Staining Digit Path&Workflow

CER=constant exchange rates 161 2015: Key planned product launches Professional Diagnostics

Product Description Region

cobas c 513 dedicated HbA1C analyzer EU  cobas t 411 core lab coagulation analyzer EU

Cobas 8100 V2 integrated pre- and post-analytical solution WW  CoaguChek Pro II professional system for PT and aPTT testing EU

HTLV human T-lymphotropic virus diagnostics test EU  Cobas h 232 Point of Care test version of Elecsys cTNT-hs EU Troponin T 

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 162 2015: Key planned product launches Molecular Diagnostics

Product Description Region

cobas® 6800/8800 medium to high volume automated real-time PCR US  cobas® 6800/8800 multiplex bloodscreening test US MPX cobas® 6800/8800 quantitative HBV viral load test EU HBV  cobas® 4800 HIV-1 quantitative HIV viral load test EU cobas® 4800 HCV quantitative HCV viral load test cobas® 4800 HBV quantitative HBV viral load test

cobas® EGFR Test v2 detection of EGFR in plasma EU  cobas® Liat POC detection US Influenza A/B + RSV

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 163 2015: Key planned product launches Tissue Diagnostics

Product Description Region

VENTANA HE 600 automated H&E staining platform WW

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 164 2015: Key planned product launches Diabetes Care

Product Description Region

Accu-Chek Active next-gen. bG meter, no coding of test strips WW no-code  Accu-Chek Connect bG meter with connectivity to smartphones, mobile US applications and cloud 

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 165 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Roche Group YTD Sept 2015 sales

Diagnostics

Foreign exchange rate information 166 CHF / USD

Monthly averages 0.99 0.97 2015 0.95 0.93 0.91 2014 0.89 0.87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Year-To-Date averages 0.99 0.97 2015 0.95 0.93 +7% +6% +6% 0.91 2014 0.89 0.87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

167 CHF / USD

0.99 monthly avg 2015 monthly avg 2014 0.97 YTD Sep 2015 avg 0.95

+4% 0.93 avg full year 2014 0.91

0.89

0.87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

168 CHF / EUR

Monthly averages 1.25 1.20 2014 1.15 1.10 2015 1.05 1.00 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Year-To-Date averages 1.25 1.20 2014 1.15 -12% -13% -13% 1.10 1.05 2015 1.00 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

169 CHF / EUR

1.25 avg full year 2014 1.20 monthly avg 2014

1.15 -12%

1.10

YTD Sep 2015 avg 1.05 monthly avg 2015

1.00 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

170 Average exchange rates

YTD Sep 15 YTD Sep 14 YTD Sep 15 vs. YTD Sep 14

USD 0.95 0.90 6%

EUR 1.06 1.22 -13%

JPY 0.79 0.87 -10%

-15% -10% -5% 0% 5% 10%

171 Exchange rate impact on sales growth In YTD Sept 2015 negative impact from EUR and JPY more than offsetting positive impact of USD Development of average exchange rates versus prior year period CHF / EUR -12.1% -13.4% -12.7% CHF / USD +6.8% +6.4% +6.1% CHF / JPY -7.8% -9.3% -9.6%

Difference in CHF / CER -1.9%p -3.0%p -3.5%p growth 5.7% 5.7% 4.8%

Sales 2.9% 2.7% 2.2% growth CER CHF 2015 growth growth vs. 2014

Q1 HY YTD 9 FY CER=constant exchange rates (avg full year 2014) 172 Exchange rate impact on sales growth In Q3 2015 negative impact from EUR and JPY more than offsetting positive impact of USD Development of average exchange rates versus prior year period CHF / EUR -12.1% -14.6% -11.4% CHF / USD +6.8% +5.9% +5.5% CHF / JPY -7.8% -10.8% -10.2%

Difference in CHF / CER -1.9%p -4.3%p -4.3%p growth 6.7% 5.7% 4.8%

2.9% Sales 2.4% growth 1.3% CER CHF 2015 growth growth vs. 2014

Q1 Q2 Q3 Q4 CER=constant exchange rates (avg full year 2014) 173 Doing now what patients need next